Renx Enterprises Corp.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 16:20

Preliminary Proxy Statement (Form PRE 14A)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

__________________________________________

SCHEDULE 14A

__________________________________________

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )

Filed by the Registrant

☒

Filed by a Party other than the Registrant

☐

Check the appropriate box:

☒

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e)(2))

☐

Definitive Proxy Statement

☐

Definitive Additional Materials

☐

Soliciting Material Pursuant to Section 240.14a-12

RENX ENTERPRISES CORP.

(Name of Registrant as Specified in Its Charter)

______________________________________________________________
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (check the appropriate box):

☒

No fee required.

☐

Fee paid previously with preliminary materials.

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Table of Contents

RenX Enterprises Corp.

990 Biscayne Boulevard, Suite 501
Miami, Florida 33132

SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON DECEMBER , 2026

November , 2026

Dear Stockholders of RenX Enterprises Corp.:

You are cordially invited to attend a Special Meeting of Stockholders (the "Special Meeting") of RenX Enterprises Corp. (the "Company") to be held at the offices of Blank Rome LLP, 1271 Avenue of the Americas, 16th Floor, New York, New York 10020, on December , 2026, beginning at 10:00 a.m. Eastern Time.

The Special Meeting has been called by the Company's Board of Directors (the "Board") to submit the following matters to stockholders:

1. To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of 4,779,333 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), upon the conversion of the 7,169 shares of the Company's Series C Convertible Preferred Stock, par value $0.001 per share ("Series C Preferred Stock"), which were issued pursuant to that Exchange Agreement, dated June 11, 2026, that the Company entered into with Index Equity US, LLC, plus additional shares of Common Stock that may become issuable upon conversion of the Series C Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series C Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the "Series C Conversion Proposal");

2. To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of 960,667 shares of Common Stock upon the conversion of the 1,441 shares of the Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Preferred Stock"), which were issued pursuant to that Exchange Agreement, dated September 30, 2026, that the Company entered into with James Burnham, plus additional shares of Common Stock that may become issuable upon conversion of the Series D Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series D Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the "Series D Conversion Proposal");

3. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), in substantially the form attached to the accompanying proxy statement as Annex A, to, at the discretion of the Board, increase the number of authorized shares of Common Stock from 500,000,000 to 525,000,000 shares (the "Authorized Increase Proposal");

4. To approve an amendment to the Company's Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Annex B, to, at the discretion of the Board, effect a reverse stock split with respect to the Company's issued and outstanding Common Stock, at a ratio of 1-for-5 to 1-for-25 (the "Range"), with the final ratio within such Range to be determined at the discretion of the Board and included in a public announcement (the "Reverse Stock Split Proposal");

Table of Contents

5. To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of up to 2,136,728 shares of Common Stock upon conversion of a senior convertible note (the "Note") in the principal amount of $1,037,283.93 (assuming such Note accrues interest at 10% for 12 months and that the conversion price is reduced to the floor price), which Note was issued pursuant to that Exchange Agreement, dated November 2, 2026, that the Company entered into with an accredited investor (the "Note Conversion Proposal"); and

6. To approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Series C Conversion Proposal, the Series D Conversion Proposal, the Authorized Increase Proposal, the Reverse Stock Split Proposal, and/or the Note Conversion Proposal (the "Adjournment Proposal").

A proxy statement describing these matters to be acted upon at the Special Meeting is attached. No other matters will be considered at the Special Meeting.

The close of business on October 28, 2026 has been fixed as the record date for the determination of stockholders of the Company entitled to notice of, and to vote at, the Special Meeting and any adjournment or postponement thereof.

Your vote is important. Whether or not you plan to attend the Special Meeting, we urge you to vote promptly.

On behalf of RenX Enterprises Corp., I thank you for your ongoing interest and investment in our company.

Sincerely,

David Villarreal

Chief Executive Officer and Director

Table of Contents

RenX Enterprises Corp.

990 Biscayne Boulevard, Suite 501
Miami, Florida 33132

November , 2026

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON DECEMBER , 2026

To the Stockholders of RenX Enterprises Corp.:

The Board of Directors (the "Board") of RenX Enterprises Corp., a Delaware corporation (the "Company"), has called for a Special Meeting of Stockholders (the "Special Meeting"), to be held at the offices of Blank Rome LLP, 1271 Avenue of the Americas, 16th Floor, New York, New York 10020, on December , 2026, beginning at 10:00 a.m. local time, for the following purposes:

1. Series C Conversion Proposal. To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of 4,779,333 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), upon the conversion of the 7,169 shares of the Company's Series C Convertible Preferred Stock, par value $0.001 per share ("Series C Preferred Stock"), which were issued pursuant to that Exchange Agreement, dated June 11, 2026, that the Company entered into with Index Equity US, LLC, plus additional shares of Common Stock that may become issuable upon conversion of the Series C Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series C Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the "Series C Conversion Proposal");

2. Series D Conversion Proposal. To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of 960,667 shares of Common Stock upon the conversion of the 1,441 shares of the Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Preferred Stock"), which were issued pursuant to that Exchange Agreement, dated September 30, 2026, that the Company entered into with James Burnham, plus additional shares of Common Stock that may become issuable upon conversion of the Series D Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series D Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the "Series D Conversion Proposal");

3. Authorized Increase Proposal. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), in substantially the form attached to the accompanying proxy statement as Annex A, to increase the number of authorized shares of Common Stock from 500,000,000 to 525,000,000 shares (the "Authorized Increase Proposal");

4. Reverse Stock Split Proposal. To approve an amendment to the Company's Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Annex B, to, at the discretion of the Board, effect a reverse stock split with respect to the Company's issued and outstanding Common Stock, at a ratio of 1-for-5 to 1-for-25 (the "Range"), with the final ratio within such Range to be determined at the discretion of the Board and included in a public announcement (the "Reverse Stock Split Proposal");

Table of Contents

5. Note Conversion Proposal. To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of up to 2,136,728 shares of Common Stock upon conversion of a senior convertible note (the "Note") in the principal amount of $1,037,283.93 (assuming such Note accrues interest at 10% for 12 months and that the conversion price is reduced to the floor price), which Note was issued pursuant to that Exchange Agreement, dated November 2, 2026, that the Company entered into with an accredited investor (the "Note Conversion Proposal"); and

6. Adjournment Proposal. To approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Series C Conversion Proposal, the Series D Conversion Proposal, the Authorized Increase Proposal, the Reverse Stock Split Proposal, and/or the Note Conversion Proposal (the "Adjournment Proposal").

No other matters will be considered at the Special Meeting.

The matters listed in this Notice are described in detail in the accompanying proxy statement. Our Board of Directors has fixed the close of business on October 28, 2026 as the record date (the "Record Date") for determining those stockholders who are entitled to notice of and to vote at the Special Meeting or any adjournment or postponement thereof. Holders of outstanding shares of our Series A Convertible Preferred Stock and shares of our Series B Non-Voting Convertible Preferred Stock are not entitled to vote on any of the matters to be presented to our stockholders for approval at the Special Meeting. Accordingly, only stockholders of record of shares of our Common Stock, Series C Preferred Stock and Series D Preferred Stock as of the close of business on the Record Date will be entitled to vote at the Special Meeting; however, pursuant to the rules of Nasdaq, holders of shares of Series C Preferred Stock are not entitled to vote any of their shares of Series C Preferred Stock on the Series C Conversion Proposal, and holders of shares of Series D Preferred Stock are not entitled to vote any of their shares of Series D Preferred Stock on the Series D Conversion Proposal. A list of the stockholders of record of our Common Stock, Series C Preferred Stock and Series D Preferred Stock as of the close of business on the Record Date will be made available for inspection at the meeting and will be available for the ten days preceding the meeting, during ordinary business hours and for any purpose germane to the Special Meeting, at the Company's offices located at 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER , 2026.

The Notice of Meeting, proxy statement and proxy card are available at www.eqproxyportal.com/43029/special. This proxy statement is being mailed and made available to our stockholders of record as of the Record Date starting on or about November , 2026.

YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN TO ATTEND THE SPECIAL MEETING IN PERSON, PLEASE SUBMIT A PROXY TO HAVE YOUR SHARES VOTED AS PROMPTLY AS POSSIBLE. RECORD HOLDERS CAN SUBMIT A PROXY VIA THE INTERNET OR THE DESIGNATED TOLL-FREE TELEPHONE NUMBER, OR BY SIGNING, DATING AND RETURNING BY MAIL THE PROXY CARD ENCLOSED WITH THE PROXY MATERIALS YOU RECEIVE IN THE MAIL. IF YOU DO NOT RECEIVE THE PROXY MATERIALS IN PRINTED FORM AND WOULD LIKE TO SUBMIT A PROXY BY MAIL, YOU MAY REQUEST A PRINTED COPY OF THE PROXY MATERIALS (INCLUDING THE PROXY) BY CONTACTING THE CORPORATE SECRETARY, RENX ENTERPRISES CORP., 990 BISCAYNE BOULEVARD, SUITE 501, MIAMI, FLORIDA 33132, OR BY PHONE AT (904) 496-0027 AND SUCH MATERIALS WILL BE SENT TO YOU. BENEFICIAL OWNERS WHOSE SHARES ARE HELD AT A BROKERAGE FIRM, OR BY A BANK OR OTHER NOMINEE, SHOULD FOLLOW THE VOTING INSTRUCTIONS THAT THEY RECEIVED FROM THE NOMINEE.

By order of the Board of Directors,

David Villarreal

Chief Executive Officer and Director

Table of Contents

SPECIAL MEETING OF STOCKHOLDERS

PROXY STATEMENT

TABLE OF CONTENTS

Page

GENERAL INFORMATION

1

SPECIAL MEETING ADMISSION

3

QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING

4

PROPOSAL 1: SERIES C CONVERSION PROPOSAL

10

PROPOSAL 2: SERIES D CONVERSION PROPOSAL

14

PROPOSAL 3: AUTHORIZED INCREASE PROPOSAL

18

PROPOSAL 4: REVERSE STOCK SPLIT PROPOSAL

21

PROPOSAL 5: NOTE CONVERSION APPROVAL PROPOSAL

32

PROPOSAL 6: ADJOURNMENT PROPOSAL

36

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

37

FORWARD-LOOKING STATEMENTS

39

WHERE YOU CAN FIND MORE INFORMATION

40

HOUSEHOLDING

41

STOCKHOLDER PROPOSALS FOR THE 2027 ANNUAL MEETING

42

ANNEX A

A-1

ANNEX B

B-1

i

Table of Contents

RenX Enterprises Corp.
990 Biscayne Boulevard, Suite 501
Miami, Florida 33132

PROXY STATEMENT

FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER , 2026

GENERAL INFORMATION

We are providing these proxy materials to holders of shares of common stock, par value $0.001 per share ("Common Stock"), Series C Convertible Preferred Stock, par value $0.001 per share ("Series C Preferred Stock"), and Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Preferred Stock"), of RenX Enterprises Corp., a Delaware corporation (referred to herein as "RenX," the "Company," "we," or "us"), in connection with the solicitation by our Board of Directors (the "Board" or "Board of Directors") of proxies to be voted at our Special Meeting of Stockholders (the "Special Meeting") to be held on December , 2026, beginning at 10:00 a.m. Eastern Time, at the offices of Blank Rome LLP, 1271 Avenue of the Americas, 16th Floor, New York, New York 10020, and at any adjournment or postponement thereof. This proxy statement is being mailed and made available to our stockholders of record entitled to vote at the Special Meeting starting on or about November , 2026.

The purpose of the Special Meeting and the matters to be acted on are summarized below. No other business will come before the Special Meeting.

Agenda Item

Board Vote
Recommendation

Page
Reference

To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of 4,779,333 shares of Common Stock, upon the conversion of the 7,169 shares of Series C Preferred Stock, which were issued pursuant to that Exchange Agreement (the "Index Exchange Agreement"), dated June 11, 2026, that the Company entered into with Index Equity US, LLC ("Index Equity"), plus additional shares of Common Stock that may become issuable upon conversion of the Series C Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series C Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the "Series C Certificate of Designation") (the "Series C Conversion Proposal").

FOR

10

To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of 960,667 shares of Common Stock, upon the conversion of 1,441 shares of Series D Preferred Stock, which were issued pursuant to that Exchange Agreement (the "Burnham Exchange Agreement"), dated September 30, 2026, that the Company entered into with James Burnham, plus additional shares of Common Stock that may become issuable upon conversion of the Series D Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series D Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (the "Series D Certificate of Designation") (the "Series D Conversion Proposal").

FOR

14

1

Table of Contents

Agenda Item

Board Vote
Recommendation

Page
Reference

To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to, at the discretion of the Board, increase the number of authorized shares of Common Stock from 500,000,000 to 525,000,000 shares (the "Authorized Increase Proposal").

FOR

18

To approve an amendment to the Company's Certificate of Incorporation to, at the discretion of the Board, effect a reverse stock split with respect to the Company's issued and outstanding Common Stock, at a ratio of 1-for-5 to 1-for-25 (the "Range"), with the final ratio within such Range to be determined at the discretion of the Board and included in a public announcement (the "Reverse Stock Split Proposal").

FOR

21

To approve, for purposes of complying with Nasdaq Rule 5635(d), the issuance of up to 2,136,728 shares of Common Stock upon conversion of a senior convertible note (the "Note") in the principal amount of $1,037,283.93 (assuming such Note accrues interest at 10% for 12 months and that the conversion price is reduced to the floor price), which Note was issued pursuant to that Exchange Agreement (the "Note Exchange Agreement"), dated November 2, 2026, that the Company entered into with an accredited investor (the "Note Investor") (the "Note Conversion Proposal").

FOR

32

To approve an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Series C Conversion Proposal, the Series D Conversion Proposal, the Authorized Increase Proposal, the Reverse Stock Split Proposal, and/or the Note Conversion Proposal (the "Adjournment Proposal").

FOR

36

Even if you plan to attend the Special Meeting, please vote in advance so that your vote will be counted if you later decide not to attend the Special Meeting.

2

Table of Contents

SPECIAL MEETING ADMISSION

Only holders of our Common Stock, Series C Preferred Stock and Series D Preferred Stock as of the close of business on October 28, 2026 (the "Record Date") may attend the Special Meeting and vote on the proposals presented at the Special Meeting. If you attend, please note that you will be asked to present government-issued identification (such as a driver's license or passport) and evidence of your share ownership of our Common Stock, Series C Preferred Stock or Series D Preferred Stock, as applicable, on the Record Date. This can be your proxy card if you are a stockholder of record. If your shares of Common Stock are held beneficially in the name of a bank, broker or other holder of record and you plan to attend the Special Meeting, you will be required to present proof of your ownership of our Common Stock on the Record Date, such as a bank or brokerage account statement or a letter from your broker or bank reflecting your ownership of our Common Stock as of the Record Date, to be admitted to the Special Meeting.

No cameras, recording equipment or electronic devices will be permitted at the Special Meeting.

3

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING

We are providing you with these proxy materials because the Board is soliciting your proxy to vote at the Special Meeting to be held on December , 2026, beginning at 10:00 a.m. Eastern Time, at the offices of Blank Rome LLP, located at 1271 Avenue of the Americas, 16th Floor, New York, New York 10020, and at any postponement or adjournment thereof.

Q: What information is contained in this proxy statement?

A: The information included in this proxy statement relates to the proposals to be considered and voted on at the Special Meeting, the voting process, and other required information.

Q: What items of business will be considered and voted on at the Special Meeting?

A: The six (6) items of business to be voted on at the Special Meeting are as follows: (1) the Series C Conversion Proposal; (2) the Series D Conversion Proposal; (3) the Authorized Increase Proposal; (4) the Reverse Stock Split Proposal; (5) the Note Conversion Proposal; and (6) the Adjournment Proposal.

Other than these proposals, no other proposals will be presented for a vote at the Special Meeting.

Q: How does the Board of Directors recommend that I vote?

A: The Board of Directors recommends that you vote your shares (1) FOR the Series C Conversion Proposal; (2) FOR the Series D Conversion Proposal; (3) FOR the Authorized Increase Proposal; (4) FOR the Reverse Stock Split Proposal; (5) FOR the Note Conversion Proposal; and (6) FOR the Adjournment Proposal. If you are a stockholder of record and you return a properly executed proxy card or vote by proxy over the Internet but do not mark the boxes showing how you wish to vote, your shares will be voted in accordance with the recommendations of the Board, as set forth above.

Q: Who is entitled to vote at the Special Meeting?

A: Only holders of record of our Common Stock, Series C Preferred Stock and Series D Preferred Stock as of the close of business on October 28, 2026, the Record Date, are entitled to notice of and to vote at the Special Meeting and at any adjournments or postponements thereof. As of the Record Date, there were 3,472,508 shares of Common Stock, 51 shares of Series C Preferred Stock (which excludes 7,118 shares of Series C Preferred Stock that are not entitled to vote at the Special Meeting due to voting restrictions set forth in the Series C Certificate of Designation) and 168 shares of Series D Preferred Stock (which excludes 1,273 shares of Series D Preferred Stock that are not entitled to vote at the Special Meeting due to voting restrictions set forth in the Series D Certificate of Designation) outstanding and entitled to vote at the Special Meeting. Notwithstanding the foregoing, pursuant to the rules of Nasdaq, holders of shares of Series C Preferred Stock are not entitled to vote any of their shares of Series C Preferred Stock on the Series C Conversion Proposal, and holders of shares of Series D Preferred Stock are not entitled to vote any of their shares of Series D Preferred Stock on the Series D Conversion Proposal.

Except as set forth herein, holders of shares of our Common Stock are entitled to one vote for each share of Common Stock held as of the Record Date. Except as set forth herein, holders of our Series C Preferred Stock and Series D Preferred Stock vote together with holders of shares of our Common Stock on an as-converted-to-Common Stock basis (based on the initial conversion price of $2.895 per share), resulting in holders of our Series C Preferred Stock and Series D Preferred Stock being entitled to 345 votes for each share of Series C Preferred Stock and 345 votes for each share of Series D Preferred Stock held as of the Record Date (subject to the limitations set forth in the Series C Certificate of Designation and Series D Certificate of Designation, respectively). Accordingly, except as set forth herein, holders of shares of Common Stock are entitled to an aggregate of 3,472,508 votes, holders of shares of Series C Preferred Stock are entitled to an aggregate of 17,595 votes, and holders of shares of Series D Preferred Stock are entitled to an aggregate of 57,960 votes on each matter being presented to stockholders for approval at the Special Meeting.

Additionally, holders of outstanding shares of our Series A Convertible Preferred Stock, par value $0.001 per share ("Series A Preferred Stock"), and shares of our Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series B Preferred Stock"), are not entitled to vote on any of the matters to be presented to our stockholders for approval at the Special Meeting.

4

Table of Contents

Q: What is the difference between holding shares as a stockholder of record and as a beneficial owner?

A: Most of our stockholders hold their shares of Common Stock through a broker or other nominee rather than directly in their own name. All holders of shares of our Series C Preferred Stock and Series D Preferred Stock hold shares in their own name. As summarized below, there are some distinctions between shares of Common Stock held of record and those owned beneficially.

Stockholder of Record: Shares Registered in Your Name

If on the Record Date your shares were registered directly in your name with the Company (in the case of the Series C Preferred Stock and Series D Preferred Stock) or the Company's transfer agent (in the case of Common Stock), Equiniti Trust Company, LLC, then you are considered a stockholder of record and this proxy statement is being sent directly to you by the Company. As the stockholder of record, you have the right to grant a proxy to vote your shares or to vote in person at the Special Meeting.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If on the Record Date your shares of Common Stock were held in a stock brokerage account or by a bank or other nominee, you are considered the "beneficial owner" of shares held in street name (also called a "street name" holder), and this proxy statement is being forwarded to you by your broker, bank or other nominee. As a beneficial owner, you have the right to direct your broker, bank or other nominee on how to vote the shares held in your account. However, since you are not a stockholder of record, you may not vote these shares in person at the Special Meeting unless you bring with you a legal proxy from the stockholder of record. A legal proxy may be obtained from your broker, bank or nominee. If you do not wish to vote in person or you will not be attending the Special Meeting, you may instruct your broker, bank or nominee to vote your shares pursuant to voting instructions you will receive from your broker, bank or nominee describing the available processes for voting your stock.

Q: What happens if I do not vote?

A: Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record and do not vote in person or by proxy by completing your proxy card or submitting your proxy through the internet or by telephone, your shares will not be voted.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If you are a beneficial owner and do not instruct your broker, bank, or other nominee how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the New York Stock Exchange (the "NYSE") deems the particular proposal to be a "routine" matter. Although our shares are not listed with the NYSE, the NYSE regulates broker-dealers and their discretion to vote on stockholder proposals. Under the NYSE rules applicable to brokers and other similar organizations that are subject to NYSE rules, brokers and nominees can use their discretion to vote "uninstructed" shares with respect to matters that are considered to be "routine" under NYSE rules, but not with respect to "non-routine" matters. When there is at least one "routine" matter to be considered at a meeting, a "broker non-vote" occurs when a separate matter is deemed "non-routine" and the broker, bank or other nominee holding shares for a beneficial owner does not have discretionary voting authority with respect to the "non-routine" matter being considered and has not received instructions from the beneficial owner. Such unvoted shares on "non-routine" matters are counted as broker non-votes.

Under the rules and interpretations of the NYSE, "non-routine" matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance proposals, even if management-supported. We believe that the Series C Conversion Proposal, the Series D Conversion Proposal, and the Note Conversion Proposal are non-routine matters and that the Authorized Increase Proposal, the Reverse Stock Split Proposal and the Adjournment Proposal will be treated by the NYSE as routine matters. Accordingly, your broker may register your shares as being present at the Special Meeting for purposes of

5

Table of Contents

determining the presence of a quorum, but not vote your shares on the Series C Conversion Proposal, the Series D Conversion Proposal, and the Note Conversion Proposal without your instructions (referred to as broker non-votes), but may vote your shares on the Authorized Increase Proposal, the Reverse Stock Split Proposal and the Adjournment Proposal even in the absence of your instruction. This belief is based on preliminary guidance from the NYSE and may be incorrect or change before the Special Meeting.

Q: What is a quorum and why is it necessary?

A: Conducting business at the Special Meeting requires a quorum. Holders of thirty-four percent (34%) of the outstanding shares of capital stock entitled to vote at the Special Meeting, present in person or represented by proxy, shall constitute a quorum. Abstentions and broker non-votes will be counted as shares that are present for determining whether the presence of a quorum is present for the transaction of business at the Special Meeting. If there is no quorum, the chairperson of the meeting or the holders of a majority of the shares represented at the meeting may adjourn the meeting to another time and place.

Q: What shares can I vote?

A: Except as otherwise set forth herein, you may vote or cause to be voted all shares of Common Stock, Series C Preferred Stock and Series D Preferred Stock owned by you as of the close of business on the Record Date. These shares include: (i) shares held directly in your name as a stockholder of record; and (ii) shares held for you, as the beneficial owner, through a broker or other nominee, such as a bank.

As noted above, holders of 7,118 of shares of Series C Preferred Stock and 1,273 shares of Series D Preferred Stock are not entitled to vote such shares on any of the proposals due to voting restrictions set forth in the Series C Certificate of Designation and Series D Certificate of Designation, respectively. Additionally, pursuant to the rules of Nasdaq, holders of shares of Series C Preferred Stock are not entitled to vote any of such shares on the Series C Conversion Proposal and holders of shares of Series D Preferred Stock are not entitled to vote any of such shares on the Series D Conversion Proposal.

Q: Are dissenters' rights or appraisal rights available with respect to any proposal?

A: Under the Delaware General Corporation Law, our stockholders are not entitled to either dissenters' rights or appraisal rights with respect to any proposal to be voted on at the Special Meeting, and we will not independently provide our stockholders with any such rights.

Q: How do I vote?

A: Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record, you can vote your shares in one of two ways: either by proxy or in person at the Special Meeting. If you choose to have your shares voted by proxy, you may submit a proxy over the internet, via telephone or by completing and returning by mail the proxy card you have received. Whichever method you use, each valid proxy received in time will be voted at the Special Meeting in accordance with your instructions.

The procedures for voting are fairly simple:

Submit a Proxy by Mail. If you choose to submit a proxy by mail, simply mark, date and sign your proxy card and return it in the postage-paid envelope provided.

Submit a Proxy by Internet. If you choose to submit a proxy by internet, go to www.voteproxy.com to complete an electronic proxy card. Have your proxy card in hand when you access the website and follow the instructions. Your internet vote must be received by 11:59 p.m. Eastern Time on December , 2026 to be counted.

Submit a Proxy by Telephone. If you choose to submit a proxy by telephone, dial 1-800-PROXIES (1-800-776-9437) in the United States or 1-201-299-4446 from foreign countries from any touch-tone telephone. Have your proxy card in hand when you call and follow the instructions. Your telephonic vote must be received by 11:59 p.m. Eastern Time on December , 2026 to be counted.

Vote at the Special Meeting. Submitting a proxy by mail, internet or telephonically will not limit your right to vote at the Special Meeting if you decide to attend the Special Meeting and vote in person.

6

Table of Contents

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If you are a beneficial owner of shares registered in the name of your broker, bank, or other nominee, you should have received a voting instruction form with these proxy materials from that organization rather than from the Company. Follow the instructions from your broker, bank or other nominee included with these proxy materials, or contact your broker, bank or other nominee to request a proxy form. Internet and telephone voting may be available to beneficial owners. Please refer to the voting instruction form provided by your broker, bank or other nominee.

As a beneficial owner, you have the right to direct your broker, bank or nominee on how to vote the shares held in your account. However, since you are not a stockholder of record, you may not vote these shares in person at the Special Meeting unless you bring with you a legal proxy from the stockholder of record. A legal proxy may be obtained from your broker, bank or other nominee.

Q: Can I change my vote or revoke my proxy?

A: You may change your vote or revoke your proxy at any time before the final vote at the Special Meeting.

Stockholder of Record: Shares Registered in Your Name

To change how your shares are voted or to revoke your proxy, if you are the record holder, you may (i) deliver to our Corporate Secretary a notice of revocation in writing at RenX Enterprises Corp., 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132, subject to the voting deadlines that are described on the proxy card; (ii) submit a later-dated proxy by mail, via internet or by telephone, subject to the voting deadlines that are described on the proxy card; or (iii) attend the Special Meeting and cast your vote in person. Attendance at the Special Meeting will not, by itself, change or revoke a proxy unless you specifically so request. The last vote received chronologically, subject to the voting deadlines that are described on the proxy card will supersede any prior votes.

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

For shares you hold beneficially, you may change or revoke your vote by following the instructions provided by your broker, bank or other nominee.

Q: What if I return a proxy card or otherwise submit a proxy but do not make specific choices?

A: If you provide specific instructions, your shares will be voted as you instruct. If you are a record holder and return a signed and dated proxy card or otherwise submit a proxy without marking voting selections, your shares will be voted in accordance with the recommendations of the Board of Directors, namely: (1) FOR the Series C Conversion Proposal; (2) FOR the Series D Conversion Proposal; (3) FOR the Authorized Increase Proposal; (4) FOR the Reverse Stock Split Proposal; (5) FOR the Note Conversion Proposal; and (6) FOR the Adjournment Proposal.

Q: What is the voting requirement to approve each of the proposals?

A:

Proposal

Vote Required

Voting
Options

Impact of
"Abstain"
Vote

Impact of
Broker
Non-Votes

Proposal 1:
Series C Conversion Proposal

The affirmative vote of a majority of the shares of stock present in person or by proxy and entitled to vote on the matter is required.

"FOR" "AGAINST" "ABSTAIN"

Counts as a vote "AGAINST" this proposal.

No Effect

Proposal 2:
Series D Conversion Proposal

The affirmative vote of a majority of the shares of stock present in person or by proxy and entitled to vote on the matter is required.

"FOR" "AGAINST" "ABSTAIN"

Counts as a vote "AGAINST" this proposal.

No Effect

7

Table of Contents

Proposal

Vote Required

Voting
Options

Impact of
"Abstain"
Vote

Impact of
Broker
Non-Votes

Proposal 3:
Authorized Increase Proposal

The affirmative vote of both (i) a majority of the votes cast by the holders of shares of our Common Stock, Series C Preferred Stock and Series D Preferred Stock present or represented and voting on the matter (voting together as a single class) and (ii) a majority of the votes cast by the holders of shares of our Common Stock present or represented and voting on the matter (voting as a separate class) is required.

"FOR" "AGAINST" "ABSTAIN"

No effect on the outcome.

None Expected

Proposal 4:
Reverse Stock Split Proposal

The affirmative vote of a majority of the votes cast by the holders of all shares of stock present or represented and voting on the matter is required.

"FOR" "AGAINST" "ABSTAIN"

No effect on the outcome.

None Expected

Proposal 5:
Note Conversion Proposal

The affirmative vote of a majority of the shares of stock present in person or by proxy and entitled to vote on the matter is required.

"FOR" "AGAINST" "ABSTAIN"

Counts as a vote "AGAINST" this proposal.

No Effect

Proposal 6:
Adjournment Proposal

The affirmative vote of a majority of the shares of stock present in person or by proxy and entitled to vote on the matter is required.

"FOR" "AGAINST" "ABSTAIN"

Counts as a vote "AGAINST" this proposal.

None Expected

Q: What should I do if I receive more than one proxy statement?

A: You may receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. If you are a stockholder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date, and return each proxy card and voting instruction card that you receive.

Q: Where can I find the voting results of the Special Meeting?

A: We intend to announce preliminary voting results at the Special Meeting and publish final results in a Current Report on Form 8-K, which will be filed within four (4) business days of the Special Meeting. If final voting results are not available to us in time to file a Current Report on Form 8-K within four (4) business days after the Special Meeting, we intend to file a Current Report on Form 8-K to publish preliminary results and, within four (4) business days after the final results are known to us, file an additional Current Report on Form 8-K to publish the final results.

Q: Who will count the votes?

A: One or more inspectors of election will tabulate the votes.

Q: Is my vote confidential?

A: Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed, either within the Company or to anyone else, except: (1) as necessary to meet applicable legal requirements; (2) to allow for the tabulation of votes and certification of the vote; or (3) to facilitate a successful proxy solicitation.

8

Table of Contents

Q: Who will bear the cost of soliciting votes for the Special Meeting?

A: We will pay all expenses incurred in connection with the solicitation of proxies. In addition to solicitation by mail, our officers, directors and regular employees, who will receive no additional compensation for their services, may solicit proxies in person or by telephone, facsimile, email or the Internet. We have requested that brokers, banks and other nominees who hold stock in their names furnish this proxy material to their customers; we will reimburse these brokers, banks and nominees for their out-of-pocket and reasonable expense. Although it is not anticipated, we reserve the right to retain a professional firm of proxy solicitors to assist in the solicitation of proxies. We estimate that we would be required to pay such firm fees ranging from $10,000 to $20,000 plus out-of-pocket expenses.

Q: Who can help answer my questions?

A: If you have any questions about the Special Meeting or how to vote, submit a proxy or revoke your proxy, or you need additional copies of this proxy statement or voting materials, you should contact the Corporate Secretary, RenX Enterprises, Corp., 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132, or by phone at (904) 496-0027.

9

Table of Contents

PROPOSAL 1
SERIES C CONVERSION PROPOSAL

Background

We are seeking stockholder approval of the issuance of 4,779,333 shares of Common Stock upon the conversion of the 7,169 outstanding shares of Series C Preferred Stock, which were issued pursuant to the Index Exchange Agreement, dated June 11, 2026, that we entered into with Index Equity, plus additional shares of Common Stock that may become issuable upon conversion of the Series C Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series C Preferred Stock set forth in the Series C Preferred Certificate of Designation.

On June 11, 2026, we entered into the Index Exchange Agreement with Index Equity, a related party, to exchange $7,169,072.79 of principal and accrued interest outstanding (the "Index Outstanding Debt") under an Amended and Restated Promissory Note (the "Index Note"), dated January 1, 2025 (originally issued to MCS Lending, LLC and assigned to Index Equity on June 9, 2026) for (i) 7,169 shares of Series C Preferred Stock, convertible at an initial conversion price of $2.895 per share into 2,476,338 shares of Common Stock, and (ii) a common stock purchase warrant (the "Series C Warrant") to purchase 619,084 shares of Common Stock, which is exercisable at a price of $2.895 per share, in each case, subject to, among other things, adjustment, shareholder approval (if required under Nasdaq rules) and certain beneficial ownership limitations. Pursuant to the Index Exchange Agreement, on June 11, 2026, we issued Index Equity the shares of Series C Preferred Stock and Series C Warrant in exchange for the Index Note and the Index Note, as well as the Index Outstanding Debt due thereunder, was cancelled.

The transaction constitutes a related-party transaction because Bjarne Borg, a director of the Company, is the manager of Index Equity.

Key Terms of the Series C Preferred Stock

The Series C Certificate of Designation provides for the following key terms:

(i) an initial $1,000 stated value per share, subject to upward adjustment at the option of the Company for dividends declared;

(ii) 8% per annum dividends (9% if not paid in cash), compounding quarterly; dividends may be paid in cash from any funds legally available for the declaration of dividends, in additional shares of Series C Preferred Stock, or by increasing the stated value on the Company's books (which would result in an increase in the number of shares issuable upon conversion of the shares of Series C Preferred Stock);

(iii) each share of Series C Preferred Stock is convertible, at the option of the holder, into that number of shares of Common Stock equal to the sum of (A) the quotient of (i) the aggregate stated value of those shares being converted, divided by (ii) the conversion price then in effect (initially $2.895 per share), plus (B) to the extent that the Company elects to pay dividends in additional shares of Series C Preferred Stock, the quotient of (X) the sum of all accrued but unpaid dividends thereon, divided by (Y) the number of shares of Series C Preferred Stock issued as a dividend divided by the stated value in effect; provided, that the conversion price is subject to standard proportional adjustment for stock dividends, stock splits or similar events, subject to a floor price of $1.50 (the "Series C Floor Price"); and provided further, that the conversion price is also subject to the full-ratchet style adjustment for dilutive issuances (as detailed in the Series C Certificate of Designation), subject to the Floor Price and with Exempt Issuances (as defined in the Series C Certificate of Designations) carved out. If a holder elects to convert following a dilutive issuance that would cause the conversion price to be less than the Series C Floor Price, then the holder would receive the number of shares of Common Stock issuable upon such conversion based upon the Series C Floor Price, plus a cash true-up for the difference;

(iv) 4.99% beneficial ownership limitation (adjustable up to 19.99% on 61 days' notice);

(v) upon a Liquidation (as defined in the Series C Certificate of Designation), holders of Series C Preferred Stock will be entitled to receive an amount in cash per share of Series C Preferred Stock equal to 150% of the stated value of such shares prior and in preference to the Common Stock and pari passu with the Company's other series of preferred stock;

10

Table of Contents

(vi) voting on an as-converted basis (calculated based on the initial conversion price of $2.895 per share) alongside holders of Common Stock as a single class, subject to the beneficial ownership limitation, Nasdaq rules and the laws of Delaware, as well as certain other limited exceptions; and

(vii) the Company may redeem outstanding shares of Series C Preferred Stock at 115% of the stated value of such shares between the 24-month and 36-month anniversaries, and 110% of stated value after the 36-month anniversary, in each case plus accrued and unpaid dividends, subject to limited exceptions.

Key Terms of the Series C Warrant

The Series C Warrant is immediately exercisable upon issuance, has a term of five years from the date of issuance, and is exercisable for up to 619,084 shares of Common Stock at an exercise price of $2.895 per share. The exercise price and number of shares issuable upon exercise thereof are subject to customary adjustments for stock dividends, stock splits or similar events. In the event of a Fundamental Transaction (as defined in the Series C Warrant), the successor entity will assume all obligations under the Series C Warrant. The holder is subject to a 4.99% beneficial ownership limitation (adjustable to up to 19.99% on 61 days' notice).

Shares Issuable Upon Conversion of the Shares of Series C Preferred Stock

If the shares of Series C Preferred Stock were to be fully converted at the initial conversion price of $2.895 per share, not taking into account any additional shares that may become issuable upon conversion of the shares of Series C Preferred Stock as a result of dividends, stock splits or similar events, up to 2,476,338 shares of Common Stock would be issuable upon such conversion. If the shares of Series C Preferred Stock were to be fully converted at the Series C Floor Price of $1.50 per share, not taking into account any additional shares that may become issuable upon conversion of the shares of Series C Preferred Stock as a result of dividends, stock splits or similar events, up to 4,779,333 shares of Common Stock could be issued upon conversion, which amount exceeds 20% of the shares of Common Stock outstanding immediately prior to execution of the Index Exchange Agreement. In addition, as further described in "Key Terms of the Series C Preferred Stock," above, holders of shares of Series C Preferred Stock are entitled to dividends payable in cash, additional shares of Series C Preferred Stock and/or by increasing the stated value, at our election. Unless we notify the holders otherwise, we currently expect that any such dividends will be paid by increasing the stated value of the shares of Series C Preferred Stock on each dividend date by the applicable dividend amount. Accordingly, the number of shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock outstanding is expected to continue to increase with each such dividend accrual, which, in turn, will result in further dilution to holders of Common Stock.

Potential Dilution to Existing Stockholders

As of the Record Date, there were 3,472,508 shares of Common Stock outstanding. If the maximum number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock at the Series C Floor Price and exercise of the Series C Warrant (5,398,417 shares, not taking into account any dividends that may be paid) were issued, such shares would represent approximately 60.9% of the shares of Common Stock outstanding as of the Record Date (on a post-issuance basis). As noted above, we currently expect that dividends on the Series C Preferred Stock will be paid by increasing the stated value of the shares of Series C Preferred Stock on each dividend date by the applicable dividend amount. Accordingly, the number of shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock outstanding is expected to continue to increase with each such dividend accrual, which, in turn, will result in further dilution to holders of Common Stock. Assuming that we were to pay all dividends payable on the Series C Preferred Stock by increasing the stated value of the shares of Series C Preferred Stock on each relevant dividend date for a period of one, two and three years, and further assuming that all such shares of Series C Preferred Stock were converted at the Series C Floor price of $1.50 per share, the shares of Series C Preferred Stock would be convertible into an aggregate of 5,224,209, 5,710,496 and 6,242,048 shares of Common Stock, respectively, as of the end of such periods.

The issuance of such shares of Common Stock upon conversion of the Series C Preferred Stock would dilute the voting power and economic interest of existing stockholders. The actual number of shares of Common Stock that may be issued will depend on the conversion price in effect at the time of conversion, which is subject to certain anti-dilution adjustments, as well as any dividends that accrue or are paid on shares of Series C Preferred Stock to the extent such dividend amounts are paid in additional shares of Series C Preferred Stock or are added to the stated value of the shares of Series C Preferred Stock. We generally do not have control over whether the holders of shares of Series C

11

Table of Contents

Preferred Stock convert their shares. For the foregoing reasons, we are unable to accurately forecast or predict with any certainty the total number of shares of Common Stock that may be issued upon conversion of the Series C Preferred Stock, and thus the ultimate magnitude of the dilutive effect cannot be conclusively determined. Future issuances of shares of Common Stock upon conversion of the Series C Preferred Stock, if any, may cause a significant reduction in the percentage economic interests of our current stockholders, and could cause the market price of our Common Stock to decline.

Reasons for Seeking Stockholder Approval

Our Common Stock is listed on the Nasdaq Capital Market, and, as such, we are subject to the applicable rules of Nasdaq. Nasdaq Listing Rule 5635(d) requires stockholder approval of transactions other than a public offering involving the sale or issuance by the issuer of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the issuer's common stock or 20% or more of the voting power outstanding before the issuance for a price that is less than the Minimum Price, regardless of whether such shares are issued to one person or group or are more widely distributed. Under Rule 5635(d), the "Minimum Price" means a price that is the lower of: (i) the closing price immediately preceding the signing of the binding agreement; or (ii) the average closing price of the common stock for the five trading days immediately preceding the signing of the binding agreement. The closing price of our Common Stock immediately preceding the signing of the Index Exchange Agreement was $1.73 per share (the "Series C Minimum Conversion Price"). In order to comply with Nasdaq Listing Rule 5635(d), the shares of Series C Preferred Stock are not convertible into shares of our Common Stock at a conversion price below $1.73 per share, the Series C Minimum Conversion Price, until stockholder approval of the conversion of the shares of Series C Preferred Stock at a price below that price, which conversion price shall in no event fall below the Series C Floor Price, is obtained.

Accordingly, we are seeking stockholder approval of the issuance of 4,779,333 shares of Common Stock upon the conversion of the 7,169 outstanding shares of Series C Preferred Stock, plus additional shares of Common Stock that may become issuable upon conversion of the Series C Preferred Stock as a result of any dividend payment or adjustment to the conversion price, at a conversion price below the Series C Minimum Conversion Price per share in order to comply with Nasdaq Listing Rule 5635.

We are not seeking the approval of our stockholders to authorize our entry into or consummation of the transactions described above, as the transactions have already been completed. Additionally, we are not seeking the approval of our stockholders to authorize the conversion of the shares of Series C Preferred Stock into shares of Common Stock at a conversion price of $1.73, the Series C Minimum Conversion Price, or above. We are only asking for approval to issue shares of Common Stock upon conversion of the shares of Series C Preferred Stock at a price below the Series C Minimum Conversion Price, subject to the Series C Floor Price.

The Board believes that approval of this proposal is in the best interests of the Company and its stockholders for the following reasons:

(1) The exchange eliminated $7.17 million in debt from the Company's balance sheet, strengthening its financial position without any new cash expenditure.

(2) Stockholder approval minimizes the likelihood that the Company will have to pay any cash true-up payments.

Potential Consequences if the Proposal is Not Approved

If this proposal is not approved, the Company will not be able to issue shares of Common Stock upon conversion of the Series C Preferred Stock at a price below $1.73 per share, the Series C Minimum Conversion Price. In that event, it is likely that the shares of Series C Preferred Stock would remain outstanding and would continue to accrue dividends at 8% per annum (or 9% if not paid in cash), compounding quarterly, which would increase the Company's obligations over time. Additionally, if the conversion price is adjusted below the Series C Floor Price at any point as a result of a Dilutive Issuance, the Company would be obligated to make cash true-up payments to the holder upon any conversion, which could adversely affect the Company's liquidity. The failure to obtain stockholder approval would not affect the validity of the Index Exchange Agreement or the issuance of the Series C Preferred Stock and the Series C Warrant, which have already been issued.

12

Table of Contents

Interests of Certain Parties

If approved by our stockholders, Index Equity, a company for which Bjarne Borg, a director of the Company, is the manager, will be entitled to convert in full the Series C Preferred Stock at a price below the Series C Minimum Conversion Price, which conversion price shall not fall below the Series C Floor Price; provided, however, that at no time will Index Equity be able to convert the shares of Series C Preferred Stock or exercise the Series C Warrant if such conversion or exercise would result in Index Equity beneficially owning in excess of 19.99% of the Company's outstanding shares of Common Stock. If the Series C Preferred Stock were fully converted at the Series C Floor Price of $1.50, Index Equity would receive up to 4,779,333 shares of Common Stock, not taking into account any additional shares that may become issuable upon conversion of the shares of Series C Preferred Stock as a result of dividends, stock splits or similar events, plus up to 619,084 shares upon exercise of the Series C Warrant, for a total of up to 5,398,417 shares. Mr. Borg, through his management of Index Equity, has a substantial interest in the approval of this proposal because stockholder approval would remove the foregoing limitations and permit full conversion of the Series C Preferred Stock, subject to the beneficial ownership limitations described above, at a price below the Series C Minimum Conversion Price.

Except as set forth herein, our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our Common Stock.

Vote Required

To be approved, this proposal must receive the affirmative vote of a majority of the shares of stock present or represented by proxy at the Special Meeting and entitled to vote on the proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote AGAINST this proposal. Broker non-votes are not expected to have any effect on this proposal.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE SERIES C CONVERSION PROPOSAL

13

Table of Contents

PROPOSAL 2
SERIES D CONVERSION PROPOSAL

Background

We are seeking stockholder approval of the issuance of 960,667 shares of Common Stock upon the conversion of the 1,441 outstanding shares of Series D Preferred Stock, which were issued pursuant to the Burnham Exchange Agreement, dated September 30, 2026, that we entered into with James Burnham, plus additional shares of Common Stock that may become issuable upon conversion of the Series D Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series D Preferred Stock set forth in the Series D Preferred Certificate of Designation.

On September 30, 2026, we entered into the Burnham Exchange Agreement with Mr. Burnham, who currently serves as our Director of Growth & M&A and previously served as a director on our Board, to exchange $1,446,774.32 of principal and accrued interest outstanding (the "Burnham Outstanding Debt") under a Promissory Note (the "Burnham Note"), dated June 2, 2025, for (i) 1,441 shares of Series D Preferred Stock, convertible at an initial conversion price of $2.895 per share into 497,754 shares of Common Stock, and (ii) a common stock purchase warrant (the "Series D Warrant") to purchase 124,438 shares of Common Stock, which is exercisable at a price of $2.895 per share, in each case, subject to, among other things, adjustment, shareholder approval (if required under Nasdaq rules) and certain beneficial ownership limitations. Pursuant to the Burnham Exchange Agreement, on September 30, 2026, we issued Mr. Burnham the shares of Series D Preferred Stock and Series D Warrant in exchange for the Burnham Note and the Burnham Note, as well as Burnham Outstanding Debt due thereunder, was cancelled.

The transaction constitutes a related-party transaction because Mr. Burnham currently serves as our Director of Growth & M&A and previously served as a director on our Board.

Key Terms of the Series D Preferred Stock

The Series D Certificate of Designation provides for the following key terms:

(i) an initial $1,000 stated value per share, subject to upward adjustment at the option of the Company for dividends declared;

(ii) 8% per annum dividends (9% if not paid in cash), compounding quarterly; dividends may be paid in cash from any funds legally available for the declaration of dividends, in additional shares of Series D Preferred Stock, or by increasing the stated value on the Company's books (which would result in an increase in the number of shares issuable upon conversion of the shares of Series D Preferred Stock);

(iii) each share of Series D Preferred Stock is convertible, at the option of the holder, into that number of shares of Common Stock equal to the sum of (A) the quotient of (i) the aggregate stated value of those shares being converted, divided by (ii) the conversion price then in effect (initially $2.895 per share), plus (B) to the extent that the Company elects to pay dividends in additional shares of Series D Preferred Stock, the quotient of (X) the sum of all accrued but unpaid dividends thereon, divided by (Y) the number of shares of Series D Preferred Stock issued as a dividend divided by the stated value in effect; provided, that the conversion price is subject to standard proportional adjustment for stock dividends, stock splits or similar events, subject to a floor price of $1.50 (the "Series D Floor Price"); and provided further, that the conversion price is also subject to the full-ratchet style adjustment for dilutive issuances (as detailed in the Series D Certificate of Designation), subject to the Floor Price and with Exempt Issuances (as defined in the Series D Certificate of Designations) carved out. If a holder elects to convert following a dilutive issuance that would cause the conversion price to be less than the Series D Floor Price, then the holder would receive the number of shares of Common Stock issuable upon such conversion based upon the Series D Floor Price, plus a cash true-up for the difference;

(iv) 4.99% beneficial ownership limitation (adjustable up to 19.99% on 61 days' notice);

(v) upon a Liquidation (as defined in the Series D Certificate of Designation), holders of Series D Preferred Stock will be entitled to receive an amount in cash per share of Series D Preferred Stock equal to 150% of the stated value of such shares prior and in preference to the Common Stock and pari passu with the Company's other series of preferred stock;

14

Table of Contents

(vi) voting on an as-converted basis (calculated based on the initial conversion price of $2.895 per share) alongside holders of Common Stock as a single class, subject to the beneficial ownership limitation, Nasdaq rules and the laws of Delaware, as well as certain other limited exceptions; and

(vii) the Company may redeem outstanding shares of Series D Preferred Stock at 115% of the stated value of such shares between the 24-month and 36-month anniversaries, and 110% of stated value after the 36-month anniversary, in each case plus accrued and unpaid dividends, subject to limited exceptions.

Key Terms of the Series D Warrant

The Series D Warrant is immediately exercisable upon issuance, has a term of five years from the date of issuance, and is exercisable for up to 124,438 shares of Common Stock at an exercise price of $2.895 per share. The exercise price and number of shares issuable upon exercise thereof are subject to customary adjustments for stock dividends, stock splits or similar events. In the event of a Fundamental Transaction (as defined in the Series D Warrant), the successor entity will assume all obligations under the Series D Warrant. The holder is subject to a 4.99% beneficial ownership limitation (adjustable to up to 19.99% on 61 days' notice).

Shares Issuable Upon Conversion of the Shares of Series D Preferred Stock

If the shares of Series D Preferred Stock were to be fully converted at the initial conversion price of $2.895 per share, not taking into account any additional shares that may become issuable upon conversion of the shares of Series D Preferred Stock as a result of dividends, stock splits or similar events, up to 497,754 shares of Common Stock would be issuable upon such conversion. If the shares of Series D Preferred Stock were to be fully converted at the Series D Floor Price of $1.50 per share, not taking into account any additional shares that may become issuable upon conversion of the shares of Series D Preferred Stock as a result of dividends, stock splits or similar events, up to 960,667 shares of Common Stock could be issued upon conversion, which amount exceeds 20% of the shares of Common Stock outstanding immediately prior to execution of the Burnham Exchange Agreement. In addition, as further described in "Key Terms of the Series D Preferred Stock," above, holders of shares of Series D Preferred Stock are entitled to dividends payable in cash, additional shares of Series D Preferred Stock and/or by increasing the stated value, at our election. Unless we notify the holders otherwise, we currently expect that any such dividends will be paid by increasing the stated value of the shares of Series D Preferred Stock on each dividend date by the applicable dividend amount. Accordingly, the number of shares of Common Stock issuable upon conversion of the shares of Series D Preferred Stock outstanding is expected to continue to increase with each such dividend accrual, which, in turn, will result in further dilution to holders of Common Stock.

Potential Dilution to Existing Stockholders

As of the Record Date, there were 3,472,508 shares of Common Stock outstanding. If the maximum number of shares of Common Stock issuable upon conversion of the Series D Preferred Stock at the Series D Floor Price and exercise of the Series D Warrant (1,085,105 shares, not taking into account any dividends that may be paid) were issued, such shares would represent approximately 23.8% of the shares of Common Stock outstanding as of the Record Date (on a post-issuance basis). As noted above, we currently expect that dividends on the Series D Preferred Stock will be paid by increasing the stated value of the shares of Series D Preferred Stock on each dividend date by the applicable dividend amount. Accordingly, the number of shares of Common Stock issuable upon conversion of the shares of Series D Preferred Stock outstanding is expected to continue to increase with each such dividend accrual, which, in turn, will result in further dilution to holders of Common Stock. Assuming that we were to pay all dividends payable on the Series D Preferred Stock by increasing the stated value of the shares of Series D Preferred Stock on each relevant dividend date for a period of one, two and three years, and further assuming that all such shares of Series D Preferred Stock were converted at the Series D Floor price of $1.50 per share, the shares of Series D Preferred Stock would be convertible into an aggregate of 1,050,088, 1,147,834 and 1,254,678 shares of Common Stock, respectively, as of the end of such periods.

The issuance of such shares of Common Stock upon conversion of the Series D Preferred Stock would dilute the voting power and economic interest of existing stockholders. The actual number of shares of Common Stock that may be issued will depend on the conversion price in effect at the time of conversion, which is subject to certain anti-dilution adjustments, as well as any dividends that accrue or are paid on shares of Series D Preferred Stock to the extent such dividend amounts are paid in additional shares of Series D Preferred Stock or are added to the stated

15

Table of Contents

value of the shares of Series D Preferred Stock. We generally do not have control over whether the holders of shares of Series D Preferred Stock convert their shares. For the foregoing reasons, we are unable to accurately forecast or predict with any certainty the total number of shares of Common Stock that may be issued upon conversion of the Series D Preferred Stock, and thus the ultimate magnitude of the dilutive effect cannot be conclusively determined. Future issuances of shares of Common Stock upon conversion of the Series D Preferred Stock, if any, may cause a significant reduction in the percentage economic interests of our current stockholders, and could cause the market price of our Common Stock to decline.

Reasons for Seeking Stockholder Approval

Our Common Stock is listed on the Nasdaq Capital Market, and, as such, we are subject to the applicable rules of Nasdaq. Nasdaq Listing Rule 5635(d) requires stockholder approval of transactions other than a public offering involving the sale or issuance by the issuer of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the issuer's common stock or 20% or more of the voting power outstanding before the issuance for a price that is less than the Minimum Price, regardless of whether such shares are issued to one person or group or are more widely distributed. Under Rule 5635(d), the "Minimum Price" means a price that is the lower of: (i) the closing price immediately preceding the signing of the binding agreement; or (ii) the average closing price of the common stock for the five trading days immediately preceding the signing of the binding agreement. The closing price of our Common Stock immediately preceding the signing of the Burnham Exchange Agreement was $2.27 per share (the "Series D Minimum Conversion Price"). In order to comply with Nasdaq Listing Rule 5635(d), the shares of Series D Preferred Stock are not convertible into shares of our Common Stock at a conversion price below $2.27 per share, the Series D Minimum Conversion Price, until stockholder approval of the conversion of the shares of Series D Preferred Stock at a price below that price, which conversion price shall in no event fall below the Series D Floor Price, is obtained.

Accordingly, we are seeking stockholder approval of the issuance of 960,667 shares of Common Stock upon the conversion of the 1,441 outstanding shares of Series D Preferred Stock, plus additional shares of Common Stock that may become issuable upon conversion of the Series D Preferred Stock as a result of any dividend payment or adjustment to the conversion price, at a conversion price below the Series D Minimum Conversion Price per share in order to comply with Nasdaq Listing Rule 5635.

We are not seeking the approval of our stockholders to authorize our entry into or consummation of the transactions described above, as the transactions have already been completed. Additionally, we are not seeking the approval of our stockholders to authorize the conversion of the shares of Series D Preferred Stock into shares of Common Stock at a conversion price of $2.27, the Series D Minimum Conversion Price, or above. We are only asking for approval to issue shares of Common Stock upon conversion of the shares of Series D Preferred Stock at a price below the Series D Minimum Conversion Price, subject to the Series D Floor Price.

The Board believes that approval of this proposal is in the best interests of the Company and its stockholders for the following reasons:

(1) The exchange eliminated $1.4 million in debt from the Company's balance sheet, strengthening its financial position without any new cash expenditure.

(2) Stockholder approval minimizes the likelihood that the Company will have to pay any cash true-up payments.

Potential Consequences if the Proposal is Not Approved

If this proposal is not approved, the Company will not be able to issue shares of Common Stock upon conversion of the Series D Preferred Stock at a price below $2.27 per share, the Series D Minimum Conversion Price. In that event, it is likely that the shares of Series D Preferred Stock would remain outstanding and would continue to accrue dividends at 8% per annum (or 9% if not paid in cash), compounding quarterly, which would increase the Company's obligations over time. Additionally, if the conversion price is adjusted below the Series D Floor Price at any point as a result of a Dilutive Issuance, the Company would be obligated to make cash true-up payments to the holder upon any conversion, which could adversely affect the Company's liquidity. The failure to obtain stockholder approval would not affect the validity of the Burnham Exchange Agreement or the issuance of the Series D Preferred Stock and the Series D Warrant, which have already been issued.

16

Table of Contents

Interests of Certain Parties

If approved by our stockholders, James Burnham, our Director of Growth & M&A and a former director on our Board, will be entitled to convert in full the Series D Preferred Stock at a price below the Series D Minimum Conversion Price, which conversion price shall not fall below the Series D Floor Price; provided, however, that at no time will Mr. Burnham be able to convert the shares of Series D Preferred Stock or exercise the Series D Warrant if such conversion or exercise would result in Mr. Burnham beneficially owning in excess of 19.99% of the Company's outstanding shares of Common Stock. If the Series D Preferred Stock were fully converted at the Series D Floor Price of $1.50, Mr. Burnham would receive up to 960,667 shares of Common Stock, not taking into account any additional shares that may become issuable upon conversion of the shares of Series D Preferred Stock as a result of dividends, stock splits or similar events, plus up to 124,438 shares upon exercise of the Series D Warrant, for a total of up to 1,085,105 shares. Mr. Burnham has a substantial interest in the approval of this proposal because stockholder approval would remove the foregoing limitations and permit full conversion of the Series D Preferred Stock, subject to the beneficial ownership limitations described above, at a price below the Series D Minimum Conversion Price.

Except as set forth herein, our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our Common Stock.

Vote Required

To be approved, this proposal must receive the affirmative vote of a majority of the shares of stock present or represented by proxy at the Special Meeting and entitled to vote on the proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote AGAINST this proposal. Broker non-votes are not expected to have any effect on this proposal.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE SERIES D CONVERSION PROPOSAL

17

Table of Contents

PROPOSAL 3
AUTHORIZED INCREASE PROPOSAL

Background

The Board has adopted a resolution setting forth a proposed amendment to its Certificate of Incorporation (a copy of which is set forth in the certificate of amendment annexed to this Proxy Statement as Annex A) to increase the number of shares of our authorized Common Stock from the 500,000,000 that are currently authorized pursuant to our Certificate of Incorporation to 525,000,000 shares of Common Stock (the "Authorized Increase"), declaring such amendment advisable, and is recommending that our stockholders approve, such proposed amendment. Such amendment will be effected after stockholder approval thereof only in the event the Board still deems it advisable. We are seeking the approval of our stockholders of the amendment of our Certificate of Incorporation to effect the Authorized Increase. If the Authorized Increase Proposal is approved by our stockholders and the Board deems it advisable, the Authorized Increase will be effected by filing a certificate of amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware. If the Board does not effect the Authorized Increase prior to the one-year anniversary of the Special Meeting, this vote will be of no further force and effect and the Board will again seek stockholder approval before implementing any such increase after that time. The Board may abandon the proposed amendment to effect the Authorized Increase at any time prior to its effectiveness, whether before or after stockholder approval thereof.

The Board of Directors proposes and recommends increasing the number of authorized shares of Common Stock from the 500,000,000 shares that are currently authorized for issuance pursuant to our Certificate of Incorporation to a total of 525,000,000 shares of Common Stock. Of our 500,000,000 shares of currently authorized Common Stock, 3,472,508 shares were outstanding as of October 28, 2026, and after taking into account (i) shares underlying outstanding shares of convertible preferred stock, convertible notes, warrants, options and restricted stock units, all assuming no limits on exercise or conversion thereof (and assuming the approval by our stockholders of the Series C Conversion Proposal and Series D Conversion Proposal), and (ii) the reservation of shares for issuance under our equity incentive plans, (iii) the number of shares of Common Stock to be issued under convertible notes that have not yet been issued but that we have a right to cause to be issued if certain conditions are met, approximately 455.0 million of the 500,000,000 shares authorized pursuant to our Certificate of Incorporation would be available for issuance.

The chart below illustrates the number of shares of Common Stock that will be available for issuance if the Authorized Increase is approved and effected. The number of shares disclosed in the column "Estimated Number of shares of Common Stock before Authorized Increase" reflects the approximate number of shares as of October 28, 2026. The number of shares disclosed in the column "Estimated number of shares of Common Stock after the Authorized Increase" gives further effect to the increase in the number of authorized shares of Common Stock from 500,000,000 to 525,000,000. The number of shares disclosed in the column "Estimated number of shares of Common Stock after the Authorized Increase" gives effect to the increase in authorized shares of Common Stock described in this proposal, but does not give effect to the Reverse Stock Split that we are seeking stockholder approval of under the Reverse Stock Split Proposal, below.

Estimated
number of
shares of
Common
Stock
before
Authorized
Increase

Estimated
number of
shares of
Common
Stock
after the
Authorized
Increase

Authorized Common Stock

500,000,000

525,000,000

Shares of Common Stock outstanding

3,472,508

3,472,508

Shares of Common Stock issuable under outstanding warrants, assuming no limits on exercise or conversion thereof

10,811,351

10,811,351

Shares of Common Stock issuable upon conversion of outstanding convertible promissory notes, assuming no limits on exercise or conversion thereof and that such convertible promissory notes accrued interest at 10% for a period of twelve (12) months and all such convertible promissory notes were converted at the applicable floor price

24,513,110

24,513,110

18

Table of Contents

Estimated
number of
shares of
Common
Stock
before
Authorized
Increase

Estimated
number of
shares of
Common
Stock
after the
Authorized
Increase

Shares of Common Stock issuable upon conversion of outstanding shares of preferred stock assuming no limits on exercise or conversion thereof (and in the case of the Series C Preferred Stock and Series D Preferred Stock, assuming conversion at the Series C Floor Price and Series D Floor Price, respectively, and not taking into account any additional shares that may become issuable upon conversion thereof as a result of any dividend payment or adjustment to the conversion price)

5,836,592

5,836,592

Shares of Common Stock issuable under outstanding stock options, assuming no limits on exercise or conversion thereof

16,670

16,670

Shares of Common Stock reserved for issuance under our equity incentive
plans

350,792

350,792

Authorized but Unissued

454,998,977

479,998,977

The Board of Directors currently believes that the Authorized Increase is advisable and in our best interest and the best interest of our stockholders. The increase in the number of authorized shares of Common Stock will provide us with flexibility in completing financing and capital raising transactions, which may be necessary for us to execute our future business plans. Other possible business and financial uses for the additional shares of Common Stock include, without limitation, attracting and retaining employees by the issuance of additional securities, and other transactions and corporate purposes that the Board may deem are in our best interest. We could also use the additional shares of Common Stock for potential strategic transactions, including, among other things, acquisitions, strategic partnerships, joint ventures, restructurings, business combinations and investments. We believe that the additional authorized shares would enable us to act quickly in response to opportunities that may arise for these types of transactions, in most cases without the necessity of obtaining further stockholder approval and holding a special stockholders' meeting before such issuance(s) could proceed, except as provided under Delaware law, as applicable, or under applicable Nasdaq rules. As of the date of this Proxy Statement, and other than upon issuance of currently outstanding securities exercisable into or convertible into the Common Stock and those additional convertible promissory notes and warrants that we may issue and sell from time to time pursuant to that Securities Purchase Agreement (the "April Purchase Agreement") that we entered into with certain accredited investors on April 30, 2026, we have no arrangements or understandings regarding the additional shares that would be authorized or immediate plans to consummate any such transactions. However, we review and evaluate potential capital raising activities, transactions and other corporate actions on an ongoing basis to determine if such actions would be in our best interest and the best interest of our stockholders. We cannot provide assurances that any such transactions will be consummated on favorable terms or at all, that they will enhance stockholder value, or that they will not adversely affect our business or the trading price of our Common Stock.

The increase in the number of shares of authorized Common Stock would not have any immediate dilutive effect on the proportionate voting power or other rights of existing stockholders.

As is true for shares presently authorized but unissued, the future issuance of shares or our Common Stock authorized by the increase in the number of authorized shares of Common Stock may, among other things, decrease existing stockholders' percentage equity ownership, could be dilutive to the voting rights of existing stockholders and, depending on the price at which they are issued could have a negative effect on the market price of our Common Stock. In addition, an increase in the number of shares of our authorized Common Stock could result in an increase in the franchise tax that we would owe to the State of Delaware.

Potential Anti-takeover Effects of the Increase

Release No. 34-15230 of the staff of the SEC requires disclosure and discussion of the effects of any action, including the proposals discussed herein, that may be used as an anti-takeover mechanism. Since the amendment to our Certificate of Incorporation will provide that the number of authorized shares of Common Stock will be 525,000,000,

19

Table of Contents

the increase in the number of shares of authorized Common Stock, if effected, will result in a relative increase in the number of authorized but unissued shares of our Common Stock vis-à-vis the outstanding shares of our Common Stock and, could, under certain circumstances, have an anti-takeover effect, although this is not the purpose or intent of the Board. It could potentially deter takeovers, including takeovers that the Board has determined are not in the best interest of our stockholders, in that additional shares could be issued (within the limits imposed by applicable law) in one or more transactions that could make a change in control or takeover more difficult. For example, we could issue additional shares so as to dilute the stock ownership or voting rights of persons seeking to obtain control without our agreement. Similarly, the issuance of additional shares to certain persons allied with our management could have the effect of making it more difficult to remove our current management by diluting the stock ownership or voting rights of persons seeking to cause such removal. The increase in the number of shares of authorized Common Stock therefore may have the effect of discouraging unsolicited takeover attempts. By potentially discouraging initiation of any such unsolicited takeover attempts, the Increase may limit the opportunity for our stockholders to dispose of their shares at the higher price generally available in takeover attempts or that may be available under a merger proposal.

Interests of Certain Parties

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our Common Stock.

Vote Required

The affirmative vote of both (i) a majority of the votes cast by the holders of shares of our Common Stock, Series C Preferred Stock and Series D Preferred Stock present or represented and voting on the Authorized Increase Proposal (voting together as a single class) and (ii) a majority of the votes cast by the holders of shares of our Common Stock present or represented and voting on the Authorized Increase Proposal (voting as a separate class) at the Special Meeting is required to approve the Authorized Increase Proposal. Since abstentions are not considered votes cast, they will have no effect on this proposal. Broker non-votes are not expected for this proposal because we believe this matter is a routine matter.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" APPROVAL OF
THE AUTHORIZED INCREASE PROPOSAL

20

Table of Contents

PROPOSAL 4
THE REVERSE STOCK SPLIT PROPOSAL

The Board of Directors has adopted a resolution setting forth a proposed amendment to our Certificate of Incorporation to effect a reverse stock split (the "Reverse Stock Split") of our issued and outstanding shares of Common Stock, a copy of which is set forth in the certificate of amendment annexed to this proxy statement as Annex B, declared such amendment advisable, and is recommending that our stockholders approve, such proposed amendment. Such amendment will be effected after stockholder approval thereof only in the event the Board of Directors still deems it advisable. Holders of our Common Stock are being asked to approve the proposal that Article IV of our Certificate of Incorporation be amended to effect a reverse stock split of the Common Stock at a ratio in the range of one (1) share of Common Stock for every five (5) shares of Common Stock to one (1) share of Common Stock for every twenty-five (25) shares of Common Stock. If the Reverse Stock Split is approved by our stockholders and if a certificate of amendment is filed with the Secretary of State of the State of Delaware, the certificate of amendment will effect the Reverse Stock Split by reducing the outstanding number of shares of Common Stock. If the Board of Directors does not implement an approved Reverse Stock Split prior to the one-year anniversary of this meeting, this vote will be of no further force and effect and the Board will again seek stockholder approval before implementing any reverse stock split after that time. The Board of Directors may abandon the proposed amendment to effect the Reverse Stock Split at any time prior to its effectiveness, whether before or after stockholder approval thereof.

As of the Record Date, the Company had 3,480,695 issued and 3,472,508 shares of Common Stock outstanding. For purposes of illustration, if the Reverse Stock Split is effected at a ratio of 1-for-5, the number of issued and outstanding shares of Common Stock after the Reverse Stock Split would be approximately 696,139 issued and 694,501 shares issued and outstanding and if the Reverse Stock Split is effected at a ratio of 1-for-25, the number of issued and outstanding shares of Common Stock after the Reverse Stock Split would be approximately 139,227 issued and 138,900 shares issued and outstanding. The Board of Directors' decision as to whether and when to effect the Reverse Stock Split will be based on a number of factors, including market conditions, existing and expected trading prices for the Common Stock, and the continued listing requirements of Nasdaq. See below for a discussion of the factors that the Board considered in determining the Reverse Stock Split ratio Range, some of which included, but was not limited to, the following: the historical trading price and trading volume of the Common Stock; the expected impact of the Reverse Stock Split on the trading market for the Common Stock in the short-term and long-term, and general market, economic conditions, and other related conditions prevailing in our industry. The Reverse Stock Split, if effected, will not change the number of authorized shares of Common Stock or Preferred Stock, or the par value of Common Stock or Preferred Stock; however, effecting the Reverse Stock Split will provide for additional shares of authorized but unissued shares of Common Stock. Notwithstanding the foregoing, if the Authorized Increase Proposal is approved, the Board may elect to amend the Company's Certificate of Incorporation to increase the number of shares of Common Stock from 500,000,000 to 525,000,000 shares of Common Stock. As of the date of this proxy statement, our current authorized number of shares of Common Stock is sufficient to satisfy all of our share issuance obligations and current share plans and we do not have any current plans, arrangements or understandings relating to the issuance of the additional shares of authorized Common Stock that will become available for issuance following the Reverse Stock Split.

If during a period of 30 consecutive business days, the bid price for our Common Stock closes below the minimum $1.00 per share, we would not be in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). Nasdaq typically provides a period of at least 180 days by which an issuer can gain compliance with the Minimum Bid Price Rule once the stock has had a closing price below $1.00 for 30 consecutive trading days. However, under Rule 5810 (c)(3)(A)(iv), a listed company is not eligible for any cure period to address a deficiency in the minimum bid price requirement in the event that it has either (i) executed a reverse stock split within the year prior to falling out of compliance, or (ii) executed one or more reverse splits within a two-year period from the date that it falls out of compliance with a cumulative ratio of 250 shares or more to one. Therefore, if we fall out of compliance with the minimum bid price requirement at any time prior to March 26, 2027 (the one-year anniversary of our most recent reverse stock split), or we fall out of compliance with the minimum bid price requirement and have effected another reverse stock split or reverse stock splits that results in a cumulative ratio of 250 shares or more to one in the two year period prior to falling out of compliance, we will not be able to obtain the benefit of the 180-day compliance period.

21

Table of Contents

In addition, under Nasdaq's continued listing rules, if in the future the market price of our Common Stock falls below the $1.00 bid price and we will have executed one or more reverse splits within a two-year period with a cumulative ratio of 250 shares or more to one, we will not be eligible for any compliance period and will face immediate suspension and delisting procedures.

Purpose and Background of the Reverse Stock Split

The Board's primary objective in asking for authority to effect a reverse split is to allow the Board to increase the per-share trading price of our Common Stock, if necessary or appropriate. If our Board does not implement the Reverse Stock Split prior to the one-year anniversary of the date on which the Reverse Stock Split is approved by our stockholders at the Special Meeting, the authority granted in this proposal to implement the Reverse Stock Split will terminate and the Reverse Stock Split will be abandoned.

As background, on January 26, 2026, we received a letter from Nasdaq notifying us that for the preceding 30 consecutive business days (December 5, 2025 through January 20, 2026), our Common Stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2). The notice had no immediate effect on the listing or trading of our Common Stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had a compliance period of 180 calendar days, or until July 27, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). On December 8, 2025, our stockholders approved and authorized us to amend our Certificate of Incorporation to effect a reverse stock split at a ratio of 1-for-5 to 1-for-20, and on March 26, 2026, we effected a 1-for-20 reverse stock split of our then-outstanding Common Stock. On April 10, 2026, we received written notice from the Listing Qualifications staff of Nasdaq notifying us that we had regained compliance with the Minimum Bid Price Requirement and that the matter had been closed.

Although we are currently in compliance with the Minimum Bid Price Requirement, no assurances can be provided that our Common Stock will continue to trade at a price above $1.00. At our 2026 Annual Meeting of Stockholders ("2026 Annual Meeting") held on June 12, 2026, our stockholders approved and authorized us to amend our Certificate of Incorporation to effect a reverse stock split at a ratio of 1-for-5 to 1-for-10 (the "Prior Reverse Stock Split Approval"). Given the Nasdaq rules that do not permit a cure period in the event that a listed company falls out of compliance in certain circumstances, as discussed elsewhere in this proposal, we are proactively asking for stockholder approval of this proposal, which includes a larger range at which we may effect a reverse stock split than the range that was approved by our stockholders at the 2026 Annual Meeting, to ensure that we are able to effect another reverse stock split prior to falling out of compliance with the Minimum Bid Price Requirement in the event that it is necessary to maintain our Nasdaq listing. If this proposal is approved, it will supersede the Prior Reverse Stock Split Approval, and the Prior Reverse Stock Split Approval will no longer be in force or effect. If this proposal is not approved, the Prior Reverse Stock Split Approval will remain in full force and effect, and we will be able to effect a reverse stock split in accordance with the terms approved by our stockholders at the 2026 Annual Meeting.

The Board of Directors believes that the failure of stockholders to approve this Reverse Stock Split Proposal could prevent us from maintaining compliance with the Minimum Bid Price Requirement and could inhibit our ability to conduct capital raising activities, among other things. If Nasdaq delists our Common Stock, then our Common Stock would likely become traded on an over-the-counter market such as those maintained by OTC Markets Group Inc., which do not have the substantial corporate governance or quantitative listing requirements for continued trading that Nasdaq has. In that event, interest in our Common Stock may decline and certain institutions may not have the ability to trade in our Common Stock, all of which could have a material adverse effect on the liquidity or trading volume of our Common Stock. If our Common Stock becomes significantly less liquid due to delisting from Nasdaq, our stockholders may not have the ability to liquidate their investments in our Common Stock as and when desired and we believe our ability to maintain analyst coverage, attractive investor interest, and have access to capital may become significantly diminished as a result.

If the stockholders approve the Reverse Stock Split Proposal and the Board determines to implement the Reverse Stock Split, we will file a certificate of amendment to amend the existing provision of our Certificate of Incorporation to effect the Reverse Stock Split. The text of the form of proposed amendment is set forth in the certificate of amendment to the Amended and Restated Certificate of Incorporation, which is annexed to this proxy statement as Annex B.

The Reverse Stock Split will be effected simultaneously for all issued and outstanding shares of Common Stock and the Reverse Stock Split Ratio will be the same for all issued and outstanding shares of Common Stock. The Reverse Stock Split will not change the number of shares of Common Stock or preferred stock authorized for issuance pursuant

22

Table of Contents

to our Certificate of Incorporation, nor will it change the number of shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock outstanding. The Reverse Stock Split will affect all of our stockholders uniformly and will not affect any stockholder's percentage ownership interests in our company, except those stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares determined in the manner set forth below under the heading "Fractional Shares." After the Reverse Stock Split, each share of the Common Stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the Common Stock now authorized. The Reverse Stock Split will not affect us continuing to be subject to the periodic reporting requirements of the Exchange Act. The Reverse Stock Split is not intended to be, and will not have the effect of, a "going private transaction" covered by Rule 13e-3 under the Exchange Act.

The Reverse Stock Split may result in some stockholders owning "odd-lots" of less than 100 shares of the Common Stock. Brokerage commissions and other costs of transactions in odd-lots are generally higher than the costs of transactions in "round-lots" of even multiples of 100 shares. In addition, we will not issue fractional shares in connection with the Reverse Stock Split, and stockholders who would have otherwise been entitled to receive such fractional shares will receive an amount in cash determined in the manner set forth below under the heading "Fractional Shares."

Following the effectiveness of the Reverse Stock Split, if approved by the stockholders and implemented by the Company, current stockholders will hold fewer shares of Common Stock.

If the Board decides to implement the Reverse Stock Split, the Company would communicate to the public, prior to the effective time of the Reverse Stock Split, additional details regarding the Reverse Stock Split (including the final Reverse Stock Split Ratio, as determined by the Board of Directors). By voting in favor of the Reverse Stock Split, you are also expressly authorizing the Board to determine not to proceed with, and to defer or to abandon, the Reverse Stock Split, in the Board of Director's sole discretion. In determining whether to implement the Reverse Stock Split following receipt of stockholder approval of the Reverse Stock Split, and which Reverse Stock Split Ratio to implement, if any, the Board may consider, among other things, various factors, such as:

• our ability to maintain our listing on the Nasdaq Capital Market;

• the historical trading price and trading volume of the Common Stock;

• the then-prevailing trading price and trading volume of the Common Stock and the expected impact of the Reverse Stock Split on the trading market for the Common Stock in the short and long term;

• the number of shares of our Common Stock authorized for issuance pursuant to our Certificate of Incorporation, the number of shares of Common Stock issued and outstanding and the number of shares of our Common Stock that may be issued upon exercise or conversion, as applicable, of outstanding derivative securities of the Company;

• which Reverse Stock Split Ratio would result in the greatest overall reduction in our administrative costs;

• the Nasdaq rules regarding reverse stock split frequency and ratio; and

• prevailing general market and economic conditions.

Reasons for the Reverse Stock Split

To increase the per share price of our Common Stock. As discussed above, the primary objective for effecting the Reverse Stock Split, should our Board choose to effect one, would be to increase the per share price of our Common Stock, if necessary in order to remain in compliance with the Minimum Bid Price Rule or to regain compliance if we should fall out of compliance. Our Board believes that, should the appropriate circumstances arise, effecting the Reverse Stock Split, could, among other things, help us to appeal to a broader range of investors, generate greater investor interest in the Company, and improve the perception of our Common Stock as an investment security. Our Common Stock is listed on the Nasdaq Capital Market and the failure to comply with the $1.00 minimum bid price requirement may possibly be cured, under certain circumstances, by effecting the Reverse Stock Split.

To potentially improve the liquidity of our Common Stock. A Reverse Stock Split could allow a broader range of institutions to invest in our Common Stock (namely, funds that are prohibited from buying stocks whose price is below certain thresholds), potentially increasing trading volume and liquidity of our Common Stock and potentially

23

Table of Contents

decreasing the volatility of our Common Stock if institutions become long-term holders of Common Stock. A Reverse Stock Split could help increase analyst and broker interest in our Common Stock, as their policies can discourage them from following or recommending companies with low stock prices. Because of the trading volatility often associated with low-priced stocks, many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Some of those policies and practices may make the processing of trades in low-priced stocks economically unattractive to brokers. Additionally, because brokers' commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, a low average price per share of common stock can result in individual stockholders paying transaction costs representing a higher percentage of their total share value than would be the case if the share price were higher. Some investors, however, may view a Reverse Stock Split negatively since it reduces the number of shares of Common Stock available in the public market. If the Reverse Stock Split Proposal is approved and the Board believes that effecting the Reverse Stock Split is in our best interest and the best interest of our stockholders, the Board may effect the Reverse Stock Split, regardless of whether our stock is at risk of delisting from Nasdaq Capital Market, for purposes of enhancing the liquidity of the Common Stock and to facilitate capital raising.

To increase the number of additional shares issuable under the Company's Certificate of Incorporation. A Reverse Stock Split will reduce the nominal number of shares of Common Stock outstanding and the number of shares of Common Stock issuable on exercise or conversion, as applicable, of outstanding warrants or convertible debentures, while leaving the number of shares issuable under our charter unchanged. A Reverse Stock Split will therefore effectively increase the number of shares of the Common Stock that we are able to issue. This effective increase will facilitate future capital fundraising on our part. Some investors may find the Common Stock more attractive if the Reverse Stock Split is effected with additional assurance that we are unlikely to be limited in our ability to access needed capital by the number of shares of our Common Stock authorized for issuance. However, other investors may find the Common Stock a less attractive investment with the knowledge that additional dilution of the Common Stock is possible.

Certain Risks Associated with a Reverse Stock Split

Reducing the number of outstanding shares of Common Stock through the Reverse Stock Split Proposal is intended, absent other factors, to increase the per share market price of our Common Stock. Other factors, however, such as our financial results, market conditions, the market perception of our business and other risks, including those set forth below and in our SEC filings and reports, may adversely affect the market price of our Common Stock. As a result, there can be no assurance that the Reverse Stock Split, if completed, will result in the intended benefits described above, that the market price of our Common Stock will remain increased following the Reverse Stock Split or that the market price of our Common Stock will not decrease in the future. In addition, under Nasdaq's continued listing rules, if in the future the market price of our Common Stock falls below the $1.00 bid price and we will have executed a reverse stock split within the prior year, we will not be eligible for any compliance period and will face an immediate delisting determination. The Nasdaq continued listing rules also provide that if in the future the market price of our Common Stock falls below the $1.00 bid price and we will have executed one or more reverse splits within a two-year period with a cumulative ratio of 250 shares or more to one, we will not be eligible for any compliance period and will face immediate suspension and delisting procedures. We have effected one reverse stock split in the two years prior to the date of this proxy statement, which was effected in March 2026, at a ratio of 1-for-20. Although our Common Stock is currently trading above $1.00, no assurances can be provided that we will be able to maintain compliance with the Nasdaq Minimum Bid Price Requirement or that we will be entitled to a cure period in the event that we fall out of compliance with the requirement.

The Reverse Stock Split May Not Result in a Sustained Increase in the Price of our Common Stock. As noted above, the principal purpose of the Reverse Stock Split Proposal is to maintain a higher average per share market closing price of our Common Stock of at least $1.00 per share in order to maintain or regain compliance with Nasdaq's Minimum Bid Price Requirement. However, the effect of the Reverse Stock Split upon the market price of our Common Stock cannot be predicted with any certainty and we cannot assure you that the Reverse Stock Split will accomplish this objective for any meaningful period of time, or at all. Our reverse stock split effected in October 2024 only accomplished this purpose for a few months.

24

Table of Contents

The Reverse Stock Split May Decrease the Liquidity of our Common Stock. The Board believes that the Reverse Stock Split may result in an increase in the market price of our Common Stock, which could lead to increased interest in our Common Stock and possibly promote greater liquidity for our stockholders. However, the Reverse Stock Split will also reduce the total number of outstanding shares of Common Stock, which may lead to reduced trading and a smaller number of market makers for our Common Stock.

The Reverse Stock Split May Result in Some Stockholders Owning "Odd Lots" That May Be More Difficult to Sell or Require Greater Transaction Costs per Share to Sell. If the Reverse Stock Split is implemented, it will increase the number of stockholders who own "odd lots" of less than 100 shares of Common Stock. A purchase or sale of less than 100 shares of Common Stock (an "odd lot" transaction) may result in incrementally higher trading costs through certain brokers, particularly "full service" brokers. Therefore, those stockholders who own less than 100 shares of Common Stock following the Reverse Stock Split may be required to pay higher transaction costs if they sell their Common Stock.

The Reverse Stock Split May Lead to a Decrease in the Overall Market Capitalization of the Company. The Reverse Stock Split may be viewed negatively by the market and, consequently, could lead to a decrease in our overall market capitalization. If the per share market price of our Common Stock does not increase in proportion to the Reverse Stock Split Ratio, then our value, as measured by our market capitalization, will be reduced.

The Reverse Stock Split May Lead to Further Dilution of our Common Stock. Since the Reverse Stock Split Proposal would reduce the number of shares of Common Stock outstanding and the number of shares of Common Stock issuable upon exercise or conversion, as applicable, of outstanding stock options, warrants, convertible preferred stock or convertible debentures, while leaving the number of shares authorized and issuable under our Certificate of Incorporation unchanged, the Reverse Stock Split would effectively increase the number of unissued shares of Common Stock that would be available for issue and could lead to dilution of the Common Stock in future financings.

Impact of a Reverse Stock Split if Implemented

A Reverse Stock Split would affect all holders of Common Stock uniformly and would not affect any stockholder's percentage ownership interests or proportionate voting power, other than with respect to fractional shares.

The other principal effects of the Reverse Stock Split will be that:

• the number of issued and outstanding shares of Common Stock (and treasury shares), if any, will be reduced proportionately based on the final Reverse Stock Split Ratio, as determined by the Board;

• based on the final Reverse Stock Split Ratio, the per share exercise price or conversion price, as applicable, of all outstanding stock options, warrants, convertible preferred stock (including shares of our Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, to the extent outstanding as of the date that the Reverse Stock Split is effected), and convertible debentures will be increased proportionately and the number of shares of Common Stock issuable upon the exercise or conversion, as applicable, of all outstanding stock options, warrants, convertible preferred stock and convertible debentures will be reduced proportionately; and

• the number of shares reserved for issuance pursuant to any outstanding equity awards and any maximum number of shares with respect to which equity awards may be granted will be reduced proportionately based on the final Reverse Stock Split Ratio.

25

Table of Contents

The following table sets forth the approximate number of shares of Common Stock that would be outstanding immediately after the Reverse Stock Split based on the current authorized number of shares of Common Stock at various exchange ratios, based on 3,480,695 shares of Common Stock actually issued and 3,472,508 outstanding as of October 28, 2026. The table does not account for fractional shares that will be paid in cash and does not take into account the requested increase in the number of authorized shares of Common Stock pursuant to the Authorized Increase Proposal, above.

Estimated
Number of
Shares of
Common Stock
Before Reverse
Stock Split

Estimated
Number of
Shares of
Common Stock
After Reverse
Stock Split on a
1-for-5 basis

Estimated
Number of
Shares of
Common Stock
After Reverse
Stock Split on a
1-for-25 basis

Authorized Common Stock(1)

500,000,000

500,000,000

500,000,000

Shares of Common Stock outstanding

3,472,508

694,501

138,900

Shares of Common Stock issuable under outstanding warrants, assuming no limits on exercise or conversion thereof

10,811,351

2,162,270

432,454

Shares of Common Stock issuable upon conversion of outstanding convertible promissory notes, assuming no limits on exercise or conversion thereof and that such convertible promissory notes accrued interest at 10% for a period of twelve (12) months and all such convertible promissory notes were converted at the applicable floor price

24,513,110

4,902,622

980,524

Shares of Common Stock issuable upon conversion of outstanding shares of preferred stock assuming no limits on exercise or conversion thereof (and in the case of the Series C Preferred Stock and Series D Preferred Stock, assuming conversion at the Series C Floor Price and Series D Floor Price, respectively, and not taking into account any additional shares that may become issuable upon conversion thereof as a result of any dividend payment or adjustment to the conversion following any stock dividend, stock split or other share combination event or dilutive issuance)

5,836,592

1,167,318

233,463

Shares of Common Stock issuable under outstanding stock options, assuming no limits on exercise or conversion thereof

16,670

3,334

666

Shares of Common Stock reserved for issuance under our equity incentive plans

350,792

70,158

14,031

We are currently authorized to issue a maximum of 500,000,000 shares of our Common Stock, which amount may be increased to 525,000,000 shares of Common Stock if the Authorized Increase Proposal is approved by our stockholders at the Special Meeting. Although the number of authorized shares of our Common Stock will not change as a result of the Reverse Stock Split, the number of shares of our Common Stock issued and outstanding will be reduced in proportion to the ratio selected by the Board. Thus, the Reverse Stock Split will effectively increase the number of authorized and unissued shares of our Common Stock available for future issuance by the amount of the reduction effected by the Reverse Stock Split.

Following the Reverse Stock Split, the Board will have the authority, subject to applicable securities laws, to issue all authorized and unissued shares without further stockholder approval, upon such terms and conditions as the Board deems appropriate. Although we consider financing opportunities from time to time, other than pursuant to the April 2026 Purchase Agreement, we do not currently have any plans, proposals or understandings to issue the additional shares that would be available if the Reverse Stock Split is approved and effected.

26

Table of Contents

Effects of the Reverse Stock Split

Management does not anticipate that our financial condition, the percentage ownership of Common Stock by management, the number of our stockholders or any aspect of our business will materially change as a result of the Reverse Stock Split. Because the Reverse Stock Split will apply to all issued and outstanding shares of Common Stock and outstanding rights to purchase Common Stock or to exercise or convert, as applicable, other securities into shares of our Common Stock, the proposed Reverse Stock Split will not alter the relative rights and preferences of existing stockholders, except to the extent the Reverse Stock Split will result in fractional shares, as discussed in more detail below.

Our Common Stock is currently registered under Section 12(b) of the Exchange Act, and we are subject to the periodic reporting and other requirements of the Exchange Act. The Reverse Stock Split will not affect the registration of our Common Stock under the Exchange Act or the listing of our Common Stock on Nasdaq Capital Market (other than to the extent it facilitates compliance with Nasdaq Capital Market continued listing standards). Following the Reverse Stock Split, our Common Stock will continue to be listed on the Nasdaq Capital Market, although it will have a new Committee on Uniform Securities Identification Procedures, or CUSIP, number.

The rights of the holders of our Common Stock will not be affected by the Reverse Stock Split, other than as a result of the treatment of fractional shares as described below. For example, a holder of 2% of the voting power of the outstanding shares of our Common Stock immediately prior to the effectiveness of the Reverse Stock Split will generally continue to hold 2% of the voting power of the outstanding shares of our Common Stock immediately after effecting the Reverse Stock Split. The number of stockholders of record will not be affected by the Reverse Stock Split (except to the extent any are cashed out as a result of holding fractional shares). If approved and implemented, the Reverse Stock Split may result in some stockholders owning "odd lots" of less than 100 shares of our Common Stock. Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are generally higher than the costs of transactions in "round lots" of even multiples of 100 shares. The Board believes, however, that these potential effects are outweighed by the benefits of the Reverse Stock Split.

Effectiveness of the Reverse Stock Split. The Reverse Stock Split, if approved by our stockholders, would become effective upon the filing and effectiveness (the "Effective Time") of an amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware, which would take place at the Board's discretion. The exact timing of the filing of the Reverse Stock Split Amendment, if filed, would be determined by the Board based on its evaluation as to when such action would be the most advantageous to us and our stockholders. In addition, the Board reserves the right, notwithstanding stockholder approval and without further action by the stockholders, to elect not to proceed with the Reverse Stock Split at any time prior to filing the Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, if the Board, in its sole discretion, determines that it is no longer in our best interests or the best interests of our stockholders to proceed with the Reverse Stock Split. If our Board does not implement the Reverse Stock Split prior to the one-year anniversary of the date on which the Reverse Stock Split is approved by our stockholders at the Special Meeting, the authority granted in this proposal to implement the Reverse Stock Split will terminate and the Reverse Stock Split will be abandoned.

Effect on Par Value; Reduction in Stated Capital. The proposed Reverse Stock Split will not affect the par value of our stock, which will remain at $0.001 per share of Common Stock and $0.001 per share of Preferred Stock. As a result, the stated capital on our balance sheet attributable to our Common Stock, which consists of the par value per share of Common Stock multiplied by the aggregate number of shares of Common Stock issued and outstanding, will be reduced in proportion to the Reverse Stock Split Ratio selected by the Board. Correspondingly, our additional paid-in capital account, which consists of the difference between our stated capital and the aggregate amount paid to the Company upon issuance of all currently outstanding shares of the Common Stock, will be increased by the amount by which the stated capital is reduced. Our stockholders' equity, in the aggregate, will remain unchanged.

Book-Entry Shares. If the Reverse Stock Split is effected, stockholders, either as direct or beneficial owners, will have their holdings electronically adjusted by our transfer agent (and, for beneficial owners, by their brokers or banks that hold in "street name" for their benefit, as the case may be) to give effect to the Reverse Stock Split. Banks, brokers, custodians or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding Common Stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split and making payment for fractional shares. If a stockholder holds shares of Common Stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee. We do not issue physical certificates to stockholders.

27

Table of Contents

Fractional Shares. We do not intend to issue fractional shares in connection with the Reverse Stock Split. And, in lieu thereof, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the effective time of the Reverse Stock Split (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the Reverse Stock Split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the Nasdaq Capital Market for the ten days preceding the Effective Time. After the Reverse Stock Split is effected, a stockholder will have no further interest in our Company with respect to its fractional share interest and persons otherwise entitled to a fractional share will not have any voting, dividend or other rights with respect thereto, except to receive the above-described cash payment. Stockholders should be aware that under the escheat laws of various jurisdictions, sums due for fractional interests that are not timely claimed after the Effective Time may be required to be paid to the designated agent for each such jurisdiction. Stockholders otherwise entitled to receive such funds, who have not received them, will have to seek to obtain such funds directly from the jurisdiction to which they were paid.

Potential Anti-takeover Effects of the Reverse Stock Split

Release No. 34-15230 of the staff of the SEC requires disclosure and discussion of the effects of any action, including the proposals discussed herein, that may be used as an anti-takeover mechanism. Since the Reverse Stock Split, if effected, will result by the amount of the reduction effected by the Reverse Stock Split in a relative increase in the number of authorized but unissued shares of our Common Stock vis-à-vis the outstanding shares of our Common Stock and, could, under certain circumstances, have an anti-takeover effect, although this is not the purpose or intent of the Board. It could potentially deter takeovers, including takeovers that the Board has determined are not in the best interest of our stockholders, in that additional shares could be issued (within the limits imposed by applicable law) in one or more transactions that could make a change in control or takeover more difficult. For example, we could issue additional shares so as to dilute the stock ownership or voting rights of persons seeking to obtain control without our agreement. Similarly, the issuance of additional shares to certain persons allied with our management could have the effect of making it more difficult to remove our current management by diluting the stock ownership or voting rights of persons seeking to cause such removal. The increase in the number of authorized but unissued shares of Common Stock therefore may have the effect of discouraging unsolicited takeover attempts. By potentially discouraging initiation of any such unsolicited takeover attempts, the Reverse Stock Split may limit the opportunity for our stockholders to dispose of their shares at the higher price generally available in takeover attempts or that may be available under a merger proposal.

Material U.S. Federal Income Tax Considerations Related to the Reverse Stock Split

The following is a general summary of the material U.S. federal income tax considerations to U.S. holders (as defined below) of the Reverse Stock Split. This discussion is based upon current provisions of the Internal Revenue Code of 1986, as amended (the "Code"), existing and proposed Treasury regulations promulgated under the Code (the "Treasury Regulations") and judicial authority and administrative interpretations, all as of the date of this document, and all of which are subject to change, possibly with retroactive effect, and are subject to differing interpretations. Changes in these authorities may cause the tax consequences to vary substantially from the consequences described below. We have not sought and will not seek an opinion of counsel or any rulings from the Internal Revenue Service (the "IRS") with respect to any of the tax considerations discussed below. As a result, there can be no assurance that the IRS will not assert, or that a court would not sustain, a position contrary to any of the conclusions set forth below.

This discussion is limited to U.S. holders (except to the extent such discussion explicitly addresses non-U.S. holders) that hold Common Stock as "capital assets" within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address any tax consequences arising under the tax on net investment income or the alternative minimum tax, nor does it address any tax consequences arising under the laws of any state, local or non-U.S. jurisdiction, U.S. federal estate or gift tax laws, or any tax treaties. Furthermore, this discussion does not address all aspects of U.S. federal income taxation that may be applicable to U.S. holders in light of their particular circumstances or to U.S. holders that may be subject to special rules under U.S. federal income tax laws, including, without limitation:

• a bank, insurance company or other financial institution;

• a tax-exempt or a governmental organization;

28

Table of Contents

• a real estate investment trust;

• an S corporation or other pass-through entity (or an investor in an S corporation or other pass-through entity);

• a regulated investment company or a mutual fund;

• a dealer or broker in stocks and securities, or currencies;

• a trader in securities that elects mark-to-market treatment;

• a holder of Common Stock that received such stock through the exercise of an employee option, pursuant to a retirement plan or otherwise as compensation;

• a person who holds Common Stock as part of a straddle, appreciated financial position, synthetic security, hedge, conversion transaction or other integrated investment or risk reduction transaction;

• a corporation that accumulates earnings to avoid U.S. federal income tax;

• a person whose functional currency is not the U.S. dollar;

• a U.S. holder who holds Common Stock through non-U.S. brokers or other non-U.S. intermediaries;

• a U.S. holder owning or treated as owning 5% or more of the Company's Common Stock;

• a person subject to Section 451(b) of the Code; or

• a former citizen or long-term resident of the United States subject to Section 877 or 877A of the Code.

If a partnership, or any entity (or arrangement) treated as a partnership for U.S. federal income tax purposes, holds Common Stock, the tax treatment of a partner in such partnership generally will depend on the status of the partner and the activities of the partnership and upon certain determinations made at the partner level. Partnerships holding Common Stock and partners in such partnerships should consult their own tax advisors about the U.S. federal income tax consequences of the Reverse Stock Split.

For purposes of this discussion, a "U.S. holder" is a beneficial owner of shares of Common Stock that is for U.S. federal income tax purposes:

• an individual citizen or resident of the United States;

• a corporation (or any other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia;

• an estate, whose income is subject to U.S. federal income tax regardless of its source; or

• a trust (i) the administration of which is subject to the primary supervision of a U.S. court and that has one or more United States persons that have the authority to control all substantial decisions of the trust or (ii) that has made a valid election under applicable Treasury Regulations to be treated as a domestic trust.

A "non-U.S. holder" is, for U.S. federal income tax purposes, a beneficial owner of shares of Common Stock that is a not a U.S. holder or a partnership for U.S. federal income tax purposes.

Tax Consequences of the Reverse Stock Split Generally

The Reverse Stock Split should constitute a "recapitalization" for U.S. federal income tax purposes. As a result, a U.S. holder of Common Stock generally should not recognize gain or loss upon the Reverse Stock Split, except with respect to cash received in lieu of a fractional share of Common Stock, as discussed below. A U.S. holder's aggregate tax basis in the shares of Common Stock received pursuant to the Reverse Stock Split should equal the aggregate tax basis of the shares of Common Stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Common Stock), and such U.S. holder's holding period in the shares of Common Stock received should include the holding period in the shares of Common Stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Common Stock surrendered to the shares of

29

Table of Contents

Common Stock received in a recapitalization pursuant to the Reverse Stock Split. U.S. holders of shares of Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.

Cash in Lieu of Fractional Shares

A U.S. holder of Common Stock that receives cash in lieu of a fractional share of Common Stock pursuant to the Reverse Stock Split and whose proportionate interest in us is reduced (after taking into account certain constructive ownership rules) should generally recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. holder's tax basis in the shares of Common Stock surrendered that is allocated to such fractional share of Common Stock. Such capital gain or loss should be long-term capital gain or loss if the U.S. holder's holding period for Common Stock surrendered exceeds one year at the effective time of the Reverse Stock Split. The deductibility of capital losses is subject to limitations. A U.S. holder that receives cash in lieu of a fractional share of our Common Stock pursuant to the Reverse Stock Split and whose proportionate interest in us is not reduced (after taking into account certain constructive ownership rules) should generally be treated as having received a distribution that will be treated first as dividend income to the extent paid out of our current or accumulated earnings and profits, and then as a tax-free return of capital to the extent of the U.S. holder's tax basis in our Common Stock, with any remaining amount being treated as capital gain. U.S. holders should consult their tax advisors regarding the tax effects to them of receiving cash in lieu of fractional shares based on their particular circumstances.

Non-U.S. Holders

Generally, non-U.S. holders will not recognize any gain or loss as a result of the Reverse Stock Split. In particular, gain or loss will not be recognized with respect to a non-U.S. holder that receives cash in lieu of a fractional share of Common Stock and whose proportionate interest in us is reduced (after taking into account certain constructive ownership rules) provided that (a) such gain or loss is not effectively connected with the conduct of a trade or business by such non-U.S. holder in the United States (or, if certain income tax treaties apply, is not attributable to a non-U.S. holder's permanent establishment in the United States), (b) with respect to a non-U.S. holder who is an individual, such non-U.S. holder is present in the United States for less than 183 days in the taxable year of the Reverse Stock Split and other conditions are met, and (c) such non-U.S. holder complies with certain certification requirements. If such gain is effectively connected with the non-U.S. holder's conduct of a trade or business in the U.S., and if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States, the non-U.S. holder will be taxed on a net income basis at the regular tax rates and in the manner applicable to U.S. holders, and if the non-U.S. holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income tax treaty, may also apply. If the non-U.S. holder is an individual present in the United States for 183 days or more in the taxable year of the Reverse Stock Split and certain other requirements are met, the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence) on the net gain from the exchange of the shares of our Common Stock, which may be offset by certain U.S.-source capital losses of the non-U.S. holder, if any.

Notwithstanding the foregoing, with respect to a non-U.S. holder that receives cash in lieu of a fractional share of our Common Stock pursuant to the Reverse Stock Split and whose proportionate interest in us is not reduced (after taking into account certain constructive ownership rules), the gain will be treated as a dividend rather than capital gain to the extent of the non-U.S. holder's ratable share of our current or accumulated earnings and profits as calculated for U.S. federal income tax purposes, then as a tax-free return of capital to the extent of (and in reduction of) the non-U.S. holder's aggregate adjusted tax basis in the shares, and any remaining amount will be treated as capital gain.

We will withhold U.S. federal income taxes equal to 30% of any cash payments made to a non-U.S. holder as a result of the Reverse Stock Split that may be treated as a dividend, unless such holder properly demonstrates that a reduced rate of U.S. federal income tax withholding or an exemption from such withholding is applicable. For example, an applicable income tax treaty may reduce or eliminate U.S. federal income tax withholding, in which case a non-U.S. holder claiming a reduction in (or exemption from) such tax must provide us with a properly completed IRS Form W-8BEN (or other appropriate IRS Form W-8) claiming the applicable treaty benefit. Alternatively, an exemption generally should apply if the non-U.S. holder's gain is effectively connected with a U.S. trade or business of such holder, and such holder provides us with an appropriate statement to that effect on a properly completed IRS Form W-8ECI.

30

Table of Contents

Non-U.S. holders should consult their own tax advisors regarding possible dividend treatment and should consult their own tax advisor regarding the U.S. federal, state, local, and foreign income and other tax consequences of the Reverse Stock Split.

Information Reporting and Backup Withholding

Cash payments received by a U.S. holder of Common Stock pursuant to the Reverse Stock Split may be subject to information reporting and may be subject to U.S. backup withholding (currently at 24%) unless such holder provides proof of an applicable exemption or a correct taxpayer identification number and otherwise complies with the applicable requirements of the backup withholding rules. In general, backup withholding and information reporting will not apply to payment of cash in lieu of a fractional share of Common Stock to a non-U.S. holder pursuant to the Reverse Stock Split if the non-U.S. holder certifies under penalties of perjury that it is a non-U.S. holder, and the applicable withholding agent does not have actual knowledge to the contrary. In certain circumstances the amount of cash paid to a non-U.S. holder in lieu of a fractional share of Common Stock, the name and address of the beneficial owner and the amount, if any, of tax withheld may be reported to the IRS. Any amount withheld under the U.S. backup withholding rules is not an additional tax and will generally be allowed as a refund or credit against the holder's U.S. federal income tax liability provided that the required information is timely furnished to the IRS.

FATCA

Under the Foreign Account Tax Compliance Act (''FATCA''), withholding taxes may apply to certain types of payments made to ''foreign financial institutions'' (as specially defined in the Code) and certain other non-United States entities. Specifically, a 30% withholding tax may be imposed on dividends on stock paid to a foreign financial institution or to a non-financial foreign entity, unless (1) the foreign financial institution undertakes certain diligence and reporting, (2) the non-financial foreign entity either certifies it does not have any substantial United States owners or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in clause (1) above, then, pursuant to an agreement between it and the U.S. Treasury or an intergovernmental agreement between, generally, the jurisdiction in which it is resident and the U.S. Treasury, it must, among other things, identify accounts held by certain United States persons or United States-owned foreign entities, annually report certain information about such accounts and withhold 30% on payments to non-compliant foreign financial institutions and certain other account holders.

Any cash paid to a non-U.S. holder as a result of the Reverse Stock Split that is treated as dividend may be subject to withholding under FATCA unless the requirements set forth above are satisfied (if applicable) and appropriate certifications are made. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our Common Stock on or after January 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our Common Stock.

Vote Required

The affirmative vote of a majority of the votes cast by the holders of all shares of stock present or represented and voting on the Reverse Stock Split Proposal at the Special Meeting is required to approve the Reverse Stock Split Proposal. Since abstentions are not considered votes cast, they will have no effect on this proposal. Broker non-votes are not expected for this proposal because we believe this matter is a routine matter.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE APPROVAL OF THE REVERSE STOCK SPLIT PROPOSAL

31

Table of Contents

PROPOSAL 5
NOTE CONVERSION APPROVAL PROPOSAL

Background

We are seeking stockholder approval of the issuance of up to 2,136,728 shares of Common Stock upon conversion of the Note in the principal amount of $1,037,283.93 (assuming the Note accrues interest at 10% for 12 months and that the conversion price is reduced to the floor price), which Note was issued pursuant to the Note Exchange Agreement, dated November 2, 2026, entered into with the Note Investor.

On November 2, 2026, we entered into the Note Exchange Agreement with the Note Investor to exchange $1,022,971.22 of principal and accrued interest outstanding under a Senior Convertible Note, dated February 12, 2026 (the "Prior Note"), for (i) the Note, in the principal amount of $1,037,283.93 (an amount equal to 110% of the outstanding principal amount of the Prior Note), which is convertible at an initial conversion price of $2.895 per share (the "Initial Note Conversion Price") into 358,301 shares of Common Stock, and (ii) a common stock purchase warrant (the "Note Exchange Warrant") to purchase 644,944 shares of Common Stock (which is equal to 180% of the face value of the Note divided by the Initial Note Conversion Price), which is exercisable at a price of $2.67 per share, in each case, subject to, among other things, adjustment, shareholder approval (to the extent required under Nasdaq rules) and certain beneficial ownership limitations. Pursuant to the Note Exchange Agreement, on November 2, 2026, we issued the Investor the New Note and Note Exchange Warrant and the Prior Note, and all outstanding debt owned thereunder, was cancelled.

Key Terms of the Note

The Note provides for the following key terms:

(i) the Note matures 12 months from the date of issuance, subject to extension under certain circumstances;

(ii) the Note bears interest at a rate of 10% per annum, and is payable in full 12 months from the date of issuance;

(iii) the Note is unsecured and is senior to all other Indebtedness (as such term is defined in the Note) of the Company and our subsidiaries;

(iv) the Note is initially convertible, at the option of the holder, at any time after the date of issuance, into that number of shares of Common Stock equal to the principal amount of the Note, plus all accrued and unpaid interest and late charges and any other unpaid amounts, at the Initial Note Conversion Price of $2.895 per share, subject to adjustment for any stock splits, stock dividends, recapitalizations and similar events; provided, however, that subject to receipt of the stockholder approval sought by this proposal, the holder of the Note shall have the right, at any time after the date of the receipt of such stockholder approval, to convert the Note or any portion thereof into shares of Common Stock at a conversion price (the "Note Alternate Conversion Price") equal to the greater of (x) a floor price of $0.534 (the "Note Conversion Floor Price") and (y) 92% of the lowest VWAP in the ten trading days prior to the date of such conversion;

(v) in the event that the Note Investor elects to convert all or a portion of the Note in an alternate conversion, and the Note Conversion Floor Price is greater than 92% of the lowest VWAP in the ten trading days prior to the applicable conversion date, then in addition to receiving a number of shares of Common Stock equal to the quotient obtained by dividing the dollar amount of the Note being converted by the Note Conversion Floor Price, the Company shall also pay to the Note Investor cash as a true-up in an amount equal to the product of (i) any bid price of the Common Stock, as reported by Bloomberg, selected by the holder from within the twenty minutes immediately preceding the delivery of the applicable conversion notice (or, if such conversion notice is delivered other than during regular trading hours on a trading day, the closing bid price on the most recent trading day ended prior to such delivery) and (ii) the difference obtained by subtracting (I) the number of shares of Common Stock delivered (or to be delivered) to the holder with respect to such alternate conversion from (II) the quotient obtained by dividing (x) the applicable amount of the Note being converted in the alternate conversion by (y) the conversion price calculated using 92%

32

Table of Contents

of the lowest VWAP in the ten trading days prior to the applicable conversion date; provided, however, that any cash true-up payments that may be required under the Note shall not exceed the three times the original principal amount of the Note;

(vi) conversion of the Note is subject to a 4.99% beneficial ownership limitation (adjustable up to 9.99% on 61 days' notice);

(vii) the Note contains customary events of default; if an event of default occurs, from and after the occurrence, and during the continuance of, such event of default, the interest rate of the Note shall automatically increase to 18% per annum until such event of default is cured;

(viii) if an event of default occurs, the holder of the Note may, regardless of whether such event of default has been cured, require us to redeem all or any portion of the Note at a price equal to the greater of (i) the product of (A) the value of the Note to be redeemed multiplied by (B) 110% and (ii) the product of (X) the value of the Note to be redeemed, divided by the Initial Note Conversion Price, multiplied by (Y) the product of (1) 110% multiplied by (2) the greatest closing sale price of the Common Stock on any trading day during the period commencing on the date immediately preceding such event of default and ending on the date we make the entire payment;

(ix) we shall not enter into or be a party to a Fundamental Transaction (as such term is defined in the Note) unless (i) the successor entity assumes in writing all of the obligations under the Note and the other transaction documents and (ii) the successor entity is a publicly traded corporation whose common stock is quoted on or listed for trading on an eligible market, as set forth in the Note; and

(x) while the Note is outstanding, subject to certain exempt issuances, if we sell, offer or grant any option or right to purchase, or otherwise dispose of or sell any equity security or equity-linked or related security, any convertible securities any preferred stock or other securities, the holder of the Note shall have the right, in its sole discretion, to require that we apply up to 30% of the gross proceeds from such sales or offers to redeem all, or any portion, of the Note at a price equal to 110% of the amount of the Note being redeemed.

Key Terms of the Note Exchange Warrant

The Note Exchange Warrant is immediately exercisable upon issuance, has a term of six years from the date of issuance, and is exercisable for up to 644,944 shares of Common Stock at an exercise price of $2.67 per share. The exercise price and number of shares issuable upon exercise thereof are subject to customary adjustments for stock dividends, stock splits or similar events. Commencing six months from the date of issuance, in the event there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the shares of Common Stock issuable upon exercise of the outstanding Note Exchange Warrant, the Note Exchange Warrant may be exercised, in whole or in part, by means of a "cashless exercise" in which case the holder will be entitled to receive a number of shares of Common Stock equal to the quotient obtained by dividing, (x) (A) as applicable, the VWAP of the Common Stock on the date immediately preceding the exercise date (if the notice of exercise is (1) both executed and delivered on a day that is not a Trading Day (as defined in the Note Exchange Warrant) or (2) both executed and delivered on a Trading Day prior to the opening of "regular trading hours) or the bid price of the Common Stock as of the time of the holder's execution of the applicable notice of exercise (if the notice of exercise is executed during "regular trading hours" on a Trading Day), less the exercise price of the Note Exchange Warrant, multiplied by (B) the number of shares of Common Stock that would be issuable upon exercise of the Note Exchange Warrant if the exercise were by means of a cash exercise rather than a cashless exercise, by (y) the price used in (A). In the event of a Fundamental Transaction (as defined in the Note Exchange Warrant), the successor entity will assume all obligations under the Note Exchange Warrant. If holders of the Common Stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the Note Exchange Warrant following such Fundamental Transaction. In certain circumstances, the holder will have the right to receive the Black Scholes Value of the Note Exchange Warrant calculated pursuant to a formula set forth in the Note Exchange Warrant, payable either in cash or in the same type or form of consideration that is being offered in certain cases and being paid to the holders of the Common Stock as described in the Note Exchange Warrant. The holder is subject to a 4.99% beneficial ownership limitation (adjustable to up to 9.99% on 61 days' notice).

33

Table of Contents

Shares Issuable Upon Conversion of the Note

If the Note were to be fully converted at the Initial Note Conversion price of $2.895 per share, without giving effect to any default interest or penalties which may accrue thereunder, up to 394,133 shares of Common Stock would be issuable upon such conversion. If the Note were to be fully converted at the Note Conversion Floor Price of $0.534 per share, without giving effect to any default interest or penalties which may accrue thereunder, up to 2,136,728 shares of Common Stock could be issuable upon such conversion, which amount exceeds 20% of the shares of Common Stock outstanding immediately prior to execution of the Note Exchange Agreement. In addition to the foregoing, the Note Exchange Warrant is exercisable for up to 644,944 shares of Common Stock.

Potential Dilution to Existing Stockholders

As of the Record Date, there were 3,472,508 shares of Common Stock outstanding. If the maximum number of shares of Common Stock issuable upon conversion of the Note and exercise of the Note Exchange Warrant (2,781,672 shares), without giving effect to any default interest or penalties which may accrue thereunder, were issued, such shares would represent approximately 44.5% of the shares of Common Stock outstanding as of the Record Date (on a post-issuance basis). The issuance of such shares would dilute the voting power and economic interest of existing stockholders. The actual number of shares that may be issued will depend on the conversion price in effect at the time of conversion, which is subject to certain anti-dilution adjustments, as well as any interest that has accrued as of such conversion date.

Reasons for Seeking Stockholder Approval

Our Common Stock is listed on the Nasdaq Capital Market, and, as such, we are subject to the applicable rules of Nasdaq. Nasdaq Listing Rule 5635(d) requires stockholder approval of transactions other than a public offering involving the sale or issuance by the issuer of common stock (or securities convertible into or exercisable for common stock) equal to 20% or more of the issuer's common stock or 20% or more of the voting power outstanding before the issuance for a price that is less than the Minimum Price, regardless of whether such shares are issued to one person or group or are more widely distributed. Under Rule 5635(d), the "Minimum Price" means a price that is the lower of: (i) the closing price immediately preceding the signing of the binding agreement; or (ii) the average closing price of the common stock for the five trading days immediately preceding the signing of the binding agreement. The closing price of our Common Stock immediately preceding the signing of the Note Exchange Agreement was $1.0387 per share (the "Note Exchange Minimum Conversion Price"). In order to comply with Nasdaq Listing Rule 5635(d), the note is not convertible into shares of our Common Stock at a conversion price below $1.0387 per share, the Note Minimum Conversion Price, until stockholder approval of the conversion of the Note at a price below that price, which conversion price shall in no event fall below the Note Conversion Floor Price.

Additionally, pursuant to the Note Exchange Agreement, we agreed to hold a meeting of stockholders to obtain the consent of the stockholders of the Company pursuant to Nasdaq Listing Rule 5635(d) for the issuance of all shares of our Common Stock that are issuable pursuant to the Note, including the shares of Common Stock that would be issuable if the conversion price were adjusted to the Note Exchange Floor Price.

Accordingly, we are seeking stockholder approval of the issuance of up to 2,136,728 shares of Common Stock upon the conversion of the Note, plus additional shares of Common Stock that may become issuable upon conversion of the Note as a result of any default interest or penalties which may accrue thereunder, at a conversion price below the Note Exchange Minimum Conversion Price per share in order to comply with Nasdaq Listing Rule 5635.

We are not seeking the approval of our stockholders to authorize our entry into or consummation of the transactions described above, as the transactions have already been completed. Additionally, we are not seeking the approval of our stockholders to authorize the conversion of the Note into shares of Common Stock at a conversion price of $1.0387, the Note Exchange Minimum Conversion Price, or above. We are only asking for approval to issue shares of Common Stock upon conversion of Note at a price below the Note Exchange Minimum Conversion Price.

34

Table of Contents

The Board believes that approval of this proposal is in the best interests of the Company and its stockholders for the following reasons:

(1) The exchange eliminated $1.0 million in debt from the Company's balance sheet, strengthening its financial position without any new cash expenditure.

(2) Stockholder approval minimizes the likelihood that the Company will have to pay the principal amount of the Note and/or any interest that may accrue thereunder.

Potential Consequences if the Proposal is Not Approved

If this proposal is not approved, the Company will not be able to issue shares of Common Stock upon conversion of the Note at a price below $1.0387 per share, the Note Exchange Minimum Conversion Price. In that event, it is likely that the Note would remain outstanding and would continue to accrue interest, which would increase the Company's repayment obligations over time. The failure to obtain stockholder approval would not affect the validity of the Note Exchange Agreement or the issuance of the Note and the Note Exchange Warrant, which have already been issued.

As discussed above, pursuant to the Exchange Agreement, we agreed to hold a meeting of stockholders no later than one hundred and twenty (120) days after the date of the Note Exchange Agreement for the purpose of obtaining stockholder approval of the matters contemplated by this proposals. If we do not receive the approvals contemplated in this proposal within 180 days of the date of the date of the Note Exchange Agreement, then we will be contractually required to bring this matter for a stockholder vote within 120 days thereafter. Accordingly, if our stockholders do not approve this proposal, we will likely be required to hold one or more additional special meetings of stockholders. The costs and expenses associated with holding such meetings could materially and adversely impact our ability to fund our business and our financial condition. It may also discourage future investors from engaging in future financings with us.

Interests of Certain Parties

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our Common Stock.

Vote Required

To be approved, this proposal must receive the affirmative vote of a majority of the shares of stock present or represented by proxy at the Special Meeting and entitled to vote on the proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote AGAINST this proposal. Broker non-votes are not expected to have any effect on this proposal.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE NOTE CONVERSION APPROVAL PROPOSAL

35

Table of Contents

PROPOSAL 6
APPROVAL OF ADJOURNMENT PROPOSAL

Background of and Rationale for the Adjournment Proposal

The Board believes if at the Special Meeting, the number of votes represented by shares of our Common Stock, present or represented and voting in favor of the Series C Conversion Proposal, the Series D Conversion Proposal, the Authorized Increase Proposal, the Reverse Stock Split Proposal, and/or the Note Conversion Proposal, is insufficient to approve any one or more of the foregoing proposals, it is in the best interests of the stockholders to enable the Board to continue to seek to obtain a sufficient number of additional votes to approve such proposal(s).

In the Adjournment Proposal, we are asking stockholders to authorize the holder of any proxy solicited by the Board to vote in favor of adjourning or postponing the Special Meeting or any adjournment or postponement thereof. If our stockholders approve this proposal, we could adjourn or postpone the Special Meeting, and any adjourned session of the Special Meeting, to use the additional time to solicit additional proxies in favor of the Series C Conversion Proposal, the Series D Conversion Proposal, the Authorized Increase Proposal, the Reverse Stock Split Proposal, and/or the Note Conversion Proposal.

Additionally, approval of the Adjournment Proposal could mean that, in the event we receive proxies representing a sufficient number of votes against the Series C Conversion Proposal, the Series D Conversion Proposal, the Authorized Increase Proposal, the Reverse Stock Split Proposal, and/or the Note Conversion Proposal, we could adjourn or postpone the Special Meeting without a vote on such proposal(s) and use the additional time to solicit the holders of those shares to change their vote in favor of such proposal(s).

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of our Common Stock.

Vote Required

To be approved, this proposal must receive the affirmative vote of a majority of the shares present or represented by proxy at the Special Meeting and entitled to vote on the proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote AGAINST this proposal. Broker non-votes are not expected for this proposal because we believe this matter is a routine matter.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE "FOR"
APPROVAL OF THE ADJOURNMENT PROPOSAL

36

Table of Contents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Common Stock

The following table sets forth certain information regarding the beneficial ownership of our Common Stock as of the Record Date by: (i) each current director, (ii) each named executive officer, (iii) each person who we know to be the beneficial owner of more than 5% of our Common Stock, and (iv) all current directors and executive officers as a group. As of the Record Date, 3,472,508 shares of our Common Stock were outstanding. Except as otherwise set forth below, the persons named in the table have sole voting and investment power with respect to all shares of our Common Stock shown as beneficially owned by them. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o RenX Enterprises Corp., 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132.

Name of Beneficial Owner

Shares of
Common Stock
Beneficially
Owned(1)

Percentage of
Common Stock
Beneficially
Owned(1)

Directors and Named Executive Officers

David Villarreal

39,473

*

Nicolai Brune

26,382

*

Bjarne Borg

158,165

​(2)(3)

4.4

%

Anthony M. Cialone

132,162

3.8

%

John Scott Magrane

7,540

​(3)

*

Jeffrey Tweedy

7,515

​(3)

*

Peter DeMaria

7,540

​(3)

*

Christopher Melton

7,515

​(3)

*

All current executive officers and directors as a group (8 persons)

386,292

​(3)

10.8

%

5% Stockholders

Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B

385,405

​(4)

9.9

%

____________

* Represents beneficial ownership of less than one percent.

(1) The securities "beneficially owned" by a person are determined in accordance with the definition of "beneficial ownership" set forth in the regulations of the SEC and, accordingly, may include securities owned by or for, among others, the spouse, children or certain other relatives of such person as well as other securities as to which the person has or shares voting or investment power. The same shares may be beneficially owned by more than one person. Shares of common stock currently issuable or issuable within 60 days of the Record Date upon the exercise of options or vesting of restricted stock units are deemed to be outstanding in computing the beneficial ownership and percentage of beneficial ownership of the person holding such securities, but they are not deemed to be outstanding in computing the percentage of beneficial ownership of any other person. Beneficial ownership does not include stock options and restricted stock units which have not vested as of, and will not vest within 60 days of the Record Date. Beneficial ownership may be disclaimed as to certain of the securities.

(2) Includes an aggregate of 60,647 shares of Common Stock directly held by Index Equity US LLC ("IEU") and Index Resource Equity LLC ("IRE"). Also includes 94,184 shares of Common Stock that could be acquired upon the conversion of 304,099 shares of the Company's Series A Preferred Stock held by IEU and IRE. Excludes (i) 2,476,338 shares of Common Stock issuable upon conversion of the 7,169 shares of Series C Preferred Stock held by IEU (assuming conversion at the initial conversion price of $2.895 per share) and (ii) 619,084 shares of Common Stock issuable upon exercise of the Series C Warrant held by IEU, in each case due to the 4.99% beneficial ownership limitations applicable to the Series C Preferred Stock and the Series C Warrant. Mr. Borg is the manager of IEU and the manager of Index Management Services LLC, which is the manager of IRE.

(3) Includes shares that could be acquired upon the exercise of stock options that are currently exercisable or exercisable within 60 days of the Record Date, as follows: 3,334 shares for Mr. Borg; 3,334 shares for Mr. Magrane; 3,334 shares for Mr. Tweedy; 3,334 shares for Mr. DeMaria; 3,334 shares for Mr. Melton, and 16,670 shares for all current directors and executive officers as a group.

(4) Includes 385,405 shares of Common Stock that could be acquired upon conversion of senior convertible promissory notes and warrants directly held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B ("Alto"), which senior convertible promissory notes and warrants include a beneficial ownership limitation of 9.99%, within 60 days of the Record Date. Excludes 4,408,809 shares of Common Stock that could be acquired upon conversion of senior convertible promissory

37

Table of Contents

notes and warrants directly held by Alto that exceed the beneficial ownership limitation. Ayrton Capital LLC, the investment manager to Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, has discretionary authority to vote and dispose of the shares held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B and may be deemed to be the beneficial owner of these shares. Waqas Khatri, in his capacity as Managing Member of Ayrton Capital LLC, may also be deemed to have investment discretion and voting power over the shares held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B. Ayrton Capital LLC and Mr. Khatri each disclaim any beneficial ownership of these shares. The address of Alto Opportunity Master Fund, SPC is c/o Ayrton LLC 55 Post Road, W, 2nd Floor, Westport, Connecticut 06880.

Series C Preferred Stock

As of the Record Date, 7,169 shares of our Series C Preferred Stock were outstanding, all of which were held by IEU. Mr. Borg, one of our directors, is the manager of IEU, and may therefore be deemed to beneficially own the shares of Series C Preferred Stock held by IEU.

Series D Preferred Stock

As of the Record Date, 1,441 shares of our Series D Preferred Stock were outstanding, all of which were held by James D. Burnham, the Company's Director of Growth & M&A and a former director.

38

Table of Contents

FORWARD-LOOKING STATEMENTS

This proxy statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. We do not assume any obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

39

Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

The Company files annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission (the "SEC"). The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically.

Copies of the foregoing documents are also available without charge upon written request to: RenX Enterprises Corp., Attention: Corporate Secretary, 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132.

40

Table of Contents

HOUSEHOLDING

In accordance with notices previously sent to many stockholders who hold their shares through a broker, bank or other holder of record ("street-name stockholders") and share a single address, only one annual report and proxy statement is being delivered to that address unless contrary instructions from any stockholder at that address were received. This practice, known as "householding," is intended to reduce our printing and postage costs. However, any such street-name stockholder residing at the same address who wishes to receive a separate copy of this proxy statement may request a copy by contacting the broker, bank or other holder of record. Alternatively, we will promptly deliver a separate copy if a street-name stockholder contacts us either by calling (904) 496-0027 or by writing to RenX Enterprises Corp., Attention: Corporate Secretary, 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132.

Street-name stockholders who are currently receiving householded materials may revoke their consent, and street-name stockholders who are not currently receiving householded materials may request householding of our future materials, by contacting Broadridge Financial Services, Inc., either by calling toll free at (866) 540-7095 or by writing to Broadridge, Householding Department, 51 Mercedes Way, Edgewood, New York 11717. If you revoke your consent, you will be removed from the "householding" program within 30 days of Broadridge's receipt of your revocation, and each stockholder at your address will receive individual copies of our future materials.

41

Table of Contents

STOCKHOLDER PROPOSALS FOR THE 2027 ANNUAL MEETING

Stockholders who intend to present proposals for inclusion in next year's proxy materials for the 2027 Annual Meeting under SEC Rule 14a-8 must submit such proposals in writing by January 15, 2027 to RenX Enterprises Corp., 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132, Attention: Corporate Secretary. Such proposals must meet the requirements of our Amended and Restated Bylaws and the SEC to be eligible for inclusion in the proxy materials for our 2027 Annual Meeting.

Generally, timely notice of any director nomination or other proposal that any stockholder intends to present at the 2027 Annual Meeting but does not intend to have included in the proxy materials prepared by the Company in connection with the 2027 Annual Meeting, must have been delivered in writing to the Corporate Secretary at the address above not less than 90 days nor more than 120 days before the first anniversary of the 2026 Annual Meeting. As a result, stockholders who intend to present proposals or director nominations directly at the 2027 Annual Meeting must give written notice to the Corporate Secretary no earlier than the close of business on February 12, 2027, and no later than the close of business on March 14, 2027. Such stockholder notice must contain the information required by our Amended and Restated Bylaws (including the information required by Rule 14a-19, if applicable) and comply with the other procedures and requirements set forth in our Amended and Restated Bylaws and will not be effective otherwise. All notices should be addressed to the Corporate Secretary, RenX Enterprises Corp., 990 Biscayne Boulevard, Suite 501, Miami, Florida 33132.

By order of the Board of Directors,

David Villarreal

Chief Executive Officer and Director

Miami, Florida
November , 2026

42

Table of Contents

Annex A

CERTIFICATE OF AMENDMENT OF THE
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
RENX ENTERPRISES CORP.

(Pursuant to Section 242 of the
General Corporation Law of the State of Delaware)

RenX Enterprises Corp. (the "Corporation"), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the "General Corporation Law"), hereby certifies as follows:

1. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law setting forth a proposed amendment to the Amended and Restated Certificate of Incorporation of the Corporation, as amended (the "Restated Certificate"), and declaring said amendment to be advisable. The requisite stockholders of the Corporation have duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law. The amendment amends the Restated Certificate of the Corporation as follows:

2. Article IV A. is hereby deleted in its entirety and replaced with the following::

A. This Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares which the Corporation is authorized to issue is Five Hundred Thirty Million (530,000,000) shares. Five Hundred Twenty-Five Million (525,000,000) shares shall be Common Stock, each having a par value of $0.001; and Five Million (5,000,000) shares shall be Preferred Stock, each having a par value of $0.001.

3. This Certificate of Amendment shall be effective at ______ Eastern Time on ________, ______.

Annex A-1

Table of Contents

IN WITNESS WHEREOF, this Corporation has caused this Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as amended, to be signed by its Chief Executive Officer this ____ day of _______, ______.

RENX ENTERPRISES CORP.

By

Name:

David Villarreal

Title:

Chief Executive Officer

Annex A-2

Table of Contents

Annex B

CERTIFICATE OF AMENDMENT OF THE
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
RENX ENTERPRISES CORP.

(Pursuant to Section 242 of the
General Corporation Law of the State of Delaware)

RenX Enterprises Corp. (the "Corporation"), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the "General Corporation Law"), hereby certifies as follows:

1. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the General Corporation Law setting forth a proposed amendment to the Amended and Restated Certificate of Incorporation of the Corporation, as amended (the "Restated Certificate"), and declaring said amendment to be advisable. The requisite stockholders of the Corporation have duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law. The amendment amends the Restated Certificate of the Corporation as follows:

2. Article IV, Section (A) of the Restated Certificate is hereby amended to add the following paragraph immediately after the first paragraph of Article IV, Section (A):

"Upon this Certificate of Amendment to the Restated Certificate becoming effective pursuant to the General Corporation Law of the State of Delaware (the "Effective Time"), the shares of the Corporation's Common Stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time and the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time shall be reclassified as and combined into a smaller number of shares such that every [____] ([__]) shares of issued and outstanding Common Stock immediately prior to the Effective Time are automatically combined into one (1) validly issued, fully paid and nonassessable share of Common Stock, par value $0.001 per share (the "Reverse Stock Split"). Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the Reverse Stock Split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the Nasdaq Capital Market for the ten (10) days preceding the Effective Time.

Each stock certificate or book-entry position that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate or book-entry position shall have been reclassified and combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time)."

3. This Certificate of Amendment shall be effective at ______ Eastern Time on ________, ______.

Annex B-1

Table of Contents

IN WITNESS WHEREOF, this Corporation has caused this Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as amended, to be signed by its Chief Executive Officer this ____ day of _______, ______.

RENX ENTERPRISES CORP.

By

Name:

David Villarreal

Title:

Chief Executive Officer

Annex B-2

Table of Contents

SPECIAL MEETING OF STOCKHOLDERS OF RENX ENTERPRISES CORP. December , 2026NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The Notice of Meeting, proxy statement and proxy card are available at - www.eqproxyportal.com/43029/special Please sign, date and mail your proxy card in the envelope provided as soon as possible. Please detach along perforated line and mail in the envelope provided. THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" PROPOSALS 1, 2, 3, 4, 5 AND 6. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x FOR AGAINST ABSTAIN 1. Approval, for purposes of complying with Nasdaq Rule 5635(d), of the issuance of 4,779,333 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), upon the conversion of the 7,169 shares of the Company's Series C Convertible Preferred Stock, par value $0.001 per share ("Series C Preferred Stock"), which were issued pursuant to that Exchange Agreement, dated June 11, 2026, that the Company entered into with Index Equity US, LLC, plus additional shares of Common Stock that may become issuable upon conversion of the Series C Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series C Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock. 2. Approval, for purposes of complying with Nasdaq Rule 5635(d), of the issuance 960,667 shares of Common Stock upon the conversion of the 1,441 shares of the Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Preferred Stock"), which were issued pursuant to that Exchange Agreement, dated September 30, 2026, that the Company entered into with James Burnham, plus additional shares of Common Stock that may become issuable upon conversion of the Series D Preferred Stock as a result of any dividend payment or adjustment to the conversion price, all issuable pursuant to the terms of the Series D Preferred Stock set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock. 3. Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to, at the discretion of the Board, increase the number of authorized shares of Common Stock from 500,000,000 to 525,000,000 shares. 4. Approval of an amendment to the Company's Certificate of Incorporation to, at the discretion of the Board, effect a reverse stock split with respect to the Company's issued and outstanding Common Stock, at a ratio of 1-for-5 to 1-for-25 (the "Range"), with the final ratio within such Range to be determined at the discretion of the Board and included in a public announcement. 5. Approval, for purposes of complying with Nasdaq Rule 5635(d), of the issuance of up to 2,136,728 shares of Common Stock upon conversion of a senior convertible note (the "Note") in the principal amount of $1,037,283.93 (assuming such Note accrues interest at 10% for 12 months and that the conversion price is reduced to the floor price), which Note was issued pursuant to that Exchange Agreement, dated November 2, 2026, that the Company entered into with an accredited investor. 6. Approval of an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposals 1, 2, 3, 4, 5 and/or 6. In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Special Meeting. This proxy when properly executed will be voted as directed herein by the undersigned stockholder. If no direction is made, this proxy will be voted FOR Proposals 1, 2, 3, 4, 5 and 6. To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method. MARK "X" HERE IF YOU PLAN TO ATTEND THE MEETING. Signature of Stockholder Date: Signature of Stockholder Date: Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person. 166847.00103/157905208v.1

Table of Contents

RENX ENTERPRISES CORP. Proxy for Special Meeting of Stockholders on December, 2026 Solicited on Behalf of the Board of Directors The undersigned hereby appoints David Villarreal and Nicolai Brune, and each of them, with full power of substitution and power to act alone, as proxies to vote all the shares of Common Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock which the undersigned would be entitled to vote if personally present and acting at the Special Meeting of Stockholders of RenX Enterprises Corp., to be held December, 2026 at 1271 Avenue of the Americas, 16th Floor, New York, New York 10020, and at any adjournments or postponements thereof, as follows: (Continued and to be signed on the reverse side) 166847.00103/157905208v.1

Renx Enterprises Corp. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 20, 2026 at 22:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]